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SUMMARY
Ovarian cancer is one of the most common female malignancies 
and is the forth leading cause of cancer death in the western 
world. It is estimated that 3-13% o f all ovarian cancers are 
familial and the tumour suppressor gene, BRCA1 , is responsible 
for almost 90% of all these familial cases.
BRCA1 is a tumour suppressor gene which spans 100 kb on 
chromosome 17q21 and contains 24 exons. The 7.8 kb mRNA 
encodes a protein o f 1863 amino acids. The structure o f BRCA1 
is not strikingly homologous to other known molecules apart 
from the presence of a ring zinc finger domain and a 10 amino 
acid granin m otif which are thought to be significant due to fact 
that they both are conserved in humans and other species 
studied.
The overall aims o f this study were to screen and characterise 
mutations in the BRCA1 gene using genomic DNA obtained 
from ovarian cancer patients from the West o f Scotland. As a 
result o f the information obtained from this study, genetic 
counselling would be possible for those who have inherited the 
mutations and for those who have a high risk o f developing the 
same condition. In this study, 48 ovarian cancer patients with a 
family history of breast and/or ovarian cancer were screened for 
germline mutations in the BRCA1 gene.
The strategy for germline mutation analysis involved the initial 
amplification o f the BRCA1 gene by polymerase chain reaction 
(PCR) using genomic DNA as a template. After initial
amplification, the product was electrophoresed in an 1% 
agarose gel in order to check for any abnormal alteration in 
size, quality and quantity o f product. If  no alteration was 
identified, further screening o f the gene was carried out using 
the single strand conformational analysis (SSCP) and the 
protein truncation test (PTT). Any differences in the band 
pattern, when compared with negative controls (in both 
techniques) were fully characterised by automated DNA 
sequencing analysis.
Using the strategy described above, 5 different alterations were 
detected on analysis o f BRCA1 coding sequences. O f these, two 
were novel missense mutations, two were polymorphisms and 
one was an unclassified variant.
The first novel missense mutation was g.3771 A>T, changing 
serine to cysteine at amino acid position 1218. This mutation is 
in the granin site at the amino acid positions 1214-1223 and the 
leucine zipper at amino acid positions 1209-1230. It is well 
known that cysteine has a very important role in stabilising the 
three-dimensional protein structure. Two cysteine residues in 
different parts o f the polypeptide chain but adjacent in the 
three-dimensional structure o f a protein can be oxidised to form 
a disulfide bridge. Disulfide bridges usually occur among 
secreted proteins and make them less susceptible to 
degradation.
The second novel missense mutation was g.1380 G>A, 
changing glutamic acid to lysine at the amino acid position 421. 
This m utation’s effect on the BRCA1 protein is unknown. 
However, this amino acid is conserved in the murine BRCA1
XX
sequence. Two different polymorphisms were also detected in 
BRCA1 coding sequence.
Patient no 28 is thought to be homozygous for polymorphism 
g.3667 A>G was also checked for possible large deletion within 
the exon 11.
The first polymorphism, g.3667 A>G, was found in four out of 
forty-eight patients and the second polymorphism, g.4427 T>C, 
was found in six out o f forty-eight patients. These two 
polymorphisms are the most frequently found in ovarian cancer 
cases and the normal population. Although, the polymorphisms 
are generally thought to be a variation in the gene sequence, 
histopathological studies suggest that the aggressiveness of 
tumour progress, histological type and survival rate may be 
related to the host variation.
In order to establish the normal population frequency, one 
hundred samples from normal population was also screened. Six 
out o f one hundred for polymorphism g.3667 A>G and 10 out 
of 100 for polymorphism g.4427 T>C were found positive for 
these polymorphisms.
An insertion o f 12 bp o f DNA was also found in intron 20 (5’- 
GTATTCCACTCC-3 ’) at IVS20+60. Three studies suggested 
that this variant is not present in any o f the subject in the 
control population analysed. It was also reported that this 
variant did not modify the correct splicing o f exon 19-21 by 
analysing the cDNA obtained from the patient’s peripheral 
blood. It is possible that a relatively large insertion in a region 
of non-repetitive DNA might affect the kinetics o f splicing and 
result in a lower level of normal mRNA from the mutant allele.
CHAPTER I
INTRODUCTION
1
1.1 CANCER
Cancer is a cellular disease, characterised by the progressive 
loss o f the organised properties of differentiated cells: growth 
control, karyotypic stability, particular morphological and 
biochemical traits, and the definite location of cells in the 
organism.
Percival Pott, the distinguished British surgeon first identified a 
environmental cause of cancer 200 years ago, namely cancer of 
the scrotum amongst chimney sweeps, due to their exposure to 
soot. The other major ideas on causes, which originated around 
the beginning of this century, include abnormalities of 
differentiation, viruses, effects o f the immune system, 
chromosome abnormalities and most importantly somatic 
mutations.
These ideas can all now be combined into the one main notion 
that cancer arises from a series o f changes in the expression of 
the genes, mostly genetic alterations that lead progressively 
from the normal to the malignant cell. It is now established that 
a tumour arises as a clonal growth, originating from genetic 
change in a single cell (Bodmer W, 1994).
In recent years, great attention has been focused on two classes 
o f gene alterations that can cause a cancer. One class -the 
oncogenes- encode products that positively regulate cell growth 
and division. Alterations in oncogenes, which lead to an 
increased amount of product, can cause uncontrolled cell 
proliferation and tumour formation. The other class -the tumour 
suppressor genes- encode products that negatively regulate cell
2
growth and division. If  both copies o f a tumour suppressor gene 
are altered, its product is inactive or only partially active, then 
the negative control may be lost and uncontrolled cell growth 
may result.
1.2. MECHANISMS RESPONSIBLE FOR 
TUMORIGENESIS
1.2.1. Oncogenes
The discovery o f the first cancer gene was based on work begun 
long before DNA was known to be the genetic material. It was 
identified by Peyton Rous in 1909 (Korf R.Bruce, 1996). It was 
initiated from a series o f experiments that started with a 
chicken which had a lump on its leg. The lump was a soft-tissue 
sarcoma. Injection o f some tumour tissue developed the same 
soft-tissue sarcoma in other chickens. The active agent was 
identified as a virus, in fact a retrovirus, and was named the 
Rous Sarcoma Virus. A decade later, one particular gene, 
named src , was found to be responsible for the transforming 
properties. When src was lost or mutated, the virus was no 
longer oncogenic. By the 1980s, approximately 20 different 
retroviruses, each with distinctive oncogenes, were known to be 
associated with cancer (table 1.1).
The breakthrough in understanding non-retroviral malignancies 
came from recognition that viral oncogenes are homologous 
with normal eukaryotic genes. These normal cellular genes are 
referred to as proto-oncogenes. The over-expression o f a proto-
3
oncogene due to regulation by the viral genome is responsible 
for its transforming properties.
On the other hand, oncogenes are normal cellular genes that, 
when their patterns of expression are changed, can cause 
neoplastic changes in the cell. There are many routes to 
oncogene activation. One o f them is a virus as mentioned 
above. The most direct route to the oncogene activation is gene 
amplification, where a block o f DNA, including an oncogene 
and some neighbouring genes, is replicated tens or hundreds of 
times in the cell, which proliferates faster than other cells in the 
tissue. One other route to oncogene activation is through 
chromosome re-arrangements. In most cases, activation of a 
proto-oncogene is not associated with a visible change in 
chromosome structure. In bladder cancer, the ras oncogene, 
which is a retrovirus oncogene, is found to be mutated at a 
single base substitution leading to an altered amino acid.
The normal roles of proto-oncogenes are also important in 
understanding the characteristics o f these genes and their 
responsibilities for the growth o f neoplastic cells. Proto­
oncogenes can be divided into four groups.
The first group o f proto-oncogenes encode growth factors. 
These growth factors are able to stimulate the proliferation of 
certain types o f cells. Overexpression, or expression of an 
aberrant protein, leads to enhanced cell proliferation.
The second group involves membrane receptors via growth 
factors. A m utation that keeps a receptor active causes 
independent cell growth and absence of proliferation control.
4
The third group are membrane associated proteins that are 
activated by signals transmitted from membrane receptors and 
transmit a signal by modification of other proteins. This group’s 
mutations lead to overexpression o f the activated form of the 
protein or insensitivity to other proteins that regulate their 
activity.
The final group controls transcription in the nucleus. Direct 
activation o f these proto-oncogenes can cause an abnormal cell 
proliferation or differentiation in the absence o f proper signals 
transmitted across the cell membrane and through the 
cytoplasm.
The largest family o f oncogenes are the tyrosine kinases, which 
catalyse the transfer o f a phosphate group from ATP to tyrosine 
residues on specific cellular proteins. Tyrosine kinases can 
either be cell surface growth factor receptors or intracellular 
kinases. The receptor tyrosine kinases have conserved overall 
primary structure which consists of an extracellular ligand 
binding, transmembrane, juxtamembrane and an intracellular 
catalytic domain. Specific growth factors have been identified 
for individual receptors such as epidermal growth factor (EGF) 
and platelet derived growth factor (PDGF). The growth factors 
bind to their specific receptors, which results in dimerisation 
and a consequent conformational change leading to auto­
phosphorylation o f the receptor on tyrosine residues. 
Phosphorylation of substrate follows and the signal is 
transmitted through defined pathways to the nucleus to 
stimulate transcription (Katsa et al. , 1997). The amplitude o f
5
the signal determines the phenotypic response to a signal, 
namely differentiation or proliferation (Marshall, 1995).
Finally, oncogenes show a dominant effect, which means that 
overexpression o f one copy, contributes to at least some 
transformed properties to the cell.
1.2.2.Tumour Suppressor Genes
Discovery o f oncogenes and proto-oncogenes helped to make 
clear that cancer could also result from inactivation o f another 
group o f genes which encode proteins that normally negatively 
regulate cellular growth. They were named tumour suppressor 
genes and their inactivation would result in unregulated growth 
(table 1.2).
The crucial point in the cell cycle is the restriction point, which 
occurs between the G1 and S phases o f mitosis. If  a cell passes 
this point it will go on to divide, otherwise it remains in G l. In 
a normal cell, the tumour suppressor genes are working and 
keeping a cell in G l phase and it therefore does not divide. If 
however the tumour suppressor gene is switched off, the cell 
becomes uncontrollable and moves out o f G l, produces a 
duplicate set o f chromosomes in S phase, and eventually 
undergoes mitosis to produce daughter cells.
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It was suggested by Knudson (1971) that there is a totally 
different class o f genetic changes in cancers that are essentially 
recessive in their action. He has suggested that if  cancer is due 
to a series o f genetic changes at the somatic level, then 
sometimes one o f those changes may be inherited in the 
germline and so be present in every cell in the body. He also 
pointed out that another mutation in the same gene, which 
occurs somatically, would be knocking out its full function. In 
other words, while the familial inherited susceptibility behaves 
as a dominant, the effect at the somatic level, which contributes 
to tumour progression, is recessive. Knudson’s hypothesis has 
come to be called the two-hit hypothesis. Most hereditary cancer 
syndromes are due to inheritance of a mutant copy o f a tumour 
suppressor gene. Therefore it has been suggested that the 
BRCA1 gene is a tumour suppressor gene because the normal 
copy o f BRCA1 invariably is mutated in breast and ovarian 
cancers that arise in women who have inherited a mutant copy 
o f BRCA1 gene.
It has also been shown that BRCA1 expression increases during 
the cell cycle, suggesting that it may have a role in regulation of 
the transcription o f genes involved in cellular proliferation 
(Gudas et al. , 1995b). Knudson’s hypothesis is also applicable 
to the BRCA1 gene, because as a tumour suppressor gene, 
BRCA1 is recessive at a cellular level and inactivation of both 
alleles is required for tumorigenesis (Holt et al., 1996).
NAME OF THE 
TUMOUR 
SUPPRESSOR 
GENE
ROLE OF THE 
TUMOUR 
SUPPRESSOR GENE
CANCERS CAUSED BY 
THE TUMOUR 
SUPPRESSOR GENE
DPC-4
Participates in a 
cytoplasmic pathway 
that inhibits cell 
division
Involved in pancreatic 
cancer
NF-1
Encodes a GTPase- 
activating protein 
(GAP), which activates 
the RAS GTPase.
Involved in neurofibromas 
and
pheochromocytomas 
o f the nervous 
system and myeloid 
leukemia
NF-2 Codes for a nuclear 
protein.
Involved in meningioma, 
schwannoma, and 
ependymoma
RB
Codes for the pRB 
protein, a 
nuclearprotein 
that is a major 
brake in the 
cell cycle
Involved in 
retinoblastoma as well 
as bone, bladder, small 
cell lung, and breast 
cancers
P53
Codes for the 
cytoplasmic p53 
protein that regulates 
cell division and can 
induce apoptosis
Involved in a wide range of 
tumours including Li- 
Fraumeni syndrome
WT1 Unknown Involved in W ilm’s tumour o f the kidneys
BRCA1 Unknown Involved in breast and ovarian cancer
BRCA2 Unknown Involved in breast cancer
Table 1.2: Tumour Suppressor Genes and their role in 
tumorigenesis.
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1.3. OVARIAN CANCER
1.3.1. Epidemiology
Ovarian cancer is one of the most common malignancies among 
women and the fourth leading cause of cancer death in America 
(Wong P.A. et al., 1995; Parker et al., 1996). Ovarian cancer is 
predominantly a disease o f perimenopausal and postmenopausal 
women: the mean age at diagnosis is 60 years (DePasquale et 
al., 1998).
There has been increased interest in familial clustering of 
ovarian cancer. Although the majority of cases are sporadic in 
occurrence, it is now estimated that 3 to 13 percent o f ovarian 
malignancies are familial (Lynch et al., 1987; Claus et al., 
1996; Narod et al., 1994). In the 1970s, Lynch et al. (1981) and 
Fraumeni et al. (1978)(Fraumeni et al., 1978) identified several 
families in which multiple cases of epithelial ovarian cancer had 
occurred. The clinical characteristics of familial ovarian cancers 
were noted to be similar in those of women without a family 
history, however, familial ovarian cancers typically shared 
advanced-stage papillary serous adenocarcinoma and survival 
was poor (Piver et al., 1993). Investigators have established at 
least three distinct phenotypes: site-specific ovarian cancer 
(SSOC), hereditary breast-ovarian cancer (HBOC), and 
hereditary nonpolyposis colon cancer/ovarian cancer syndrome 
(Lynch syndrome II). The most important parameters used in 
making a diagnosis o f hereditary breast or ovarian cancer 
syndromes are the total number of family members affected 
with cancer and their early age o f onset (Easton et al., 1993).
10
According to The Breast and Cancer Linkage Consortium, 3 
cases o f ovarian cancer in first-degree relatives are considered 
to be hereditary. A family with a total number o f 5 cases of 
breast or ovarian cancers, including 2 cancers o f each type, 
qualifies as the breast-ovarian cancer syndrome (Easton et al., 
1993).
1.3.2. Histology
The predominant histological type o f hereditary ovarian cancer 
is serous papillary cystadenocarcinoma (Bewtra et al., 1992). 
The other major histological type is mucinous carcinoma, 
however, it has been found less frequently in hereditary ovarian 
cancers (Greggi et al., 1990; Narod et al., 1994). A third and 
very rare form is pseudomucinous carcinoma. It has been 
reported that BRCA1-linked ovarian cancers have a higher risk 
of producing a serous papillary cystadenocarcinoma (Bewtra et 
al., 1992).
1.3.3. Co-factors
A number of risk factors have been associated with the 
development of ovarian cancer, including a family history, 
nulliparity or low parity. Some other factors that increase the 
risk are, exogenous chemicals like asbestos or talc (Longo & 
Young, 1979), and dietary factors such as high consumption of 
animal fats (Rose et al., 1986). There are also a number of 
factors thought to decrease the risk, including high parity, 
breast-feeding and oral contraceptive use (DePasquale et al., 
1998; Narod et al., 1995).
l i
1.3.4. Age-of-Onset
Early age-of-onset is not as predictable o f hereditary ovarian 
cancer as it is for hereditary breast cancer. However, Amos et 
al. (1992) found that the age-of-onset o f hereditary ovarian 
cancer patients (those who have two or more relatives affected 
with ovarian cancer) was younger than expected. The median 
age o f diagnosis o f hereditary ovarian cancer was 47 years, 
which was 14 years earlier than the US median for all ovarian 
cancers.
On the other hand, although the penetrance of breast and ovarian 
cancer in carriers of the BRCA1 gene are high, it is likely that 
estimates based on selected large multicase families are inflated by 
selection bias. In addition, the proportion of breast or ovarian 
cancers related to the genes is similarly lower in population-based 
samples than in referred selected families, and, even for subjects 
with cancer onset at young ages or with a family history, it is quite 
small (Elwood, 1999).
1.3.5. Population Genetics
A family history o f ovarian cancer is a consistent risk factor for 
ovarian cancer. Based on the records of the Office o f Population 
Censuses and Surveys (UK), it was found that the life-time risk 
o f death from ovarian cancer was 1 in 40 when one relative was 
affected, which is 3 times greater than the general population 
risk. If  a woman had an affected mother and sister, or two 
affected sister, the risk became 30-40% (Ponder et al. , 1991).
It is established that familial ovarian cancer often strikes during 
the fourth and fifth decades of life and the estimated lifetime
12
risk of ovarian cancer is 60% in BRCA 1 carriers (Easton et al., 
1995; Easton et al., 1993; Easton et al., 1993).
1.3.6. M olecular Basis of Ovarian Cancer
Mary-Claire K ing’s group first demonstrated in 1990 that a 
fraction o f familial breast cancer was linked to a location on 
chromosome 17q (Hall J. et al., 1990). The following year, 
Narod et al. (Narod et al., 1991) reported that families with 
both breast and ovarian cancer also showed linkage to 17q. The 
responsible gene was mapped to (Bowcock et al., 1993; Kelsell 
et al., 1993; Neuhausen et al., 1994) and cloned and named 
BRCA1 in 1994(Miki et al., 1994a). In addition to the discovery 
of BRCA1, evidence has been found for the existence of a 
second gene, BRCA2, which is located on chromosome 13q and 
which also confers increased risk o f breast and ovarian cancer 
within high-risk breast and ovarian cancer families (Wooster et 
al., 1994). According to studies in families selected on the basis 
of strong family history and early age o f onset, germline 
mutations in BRCA1 are responsible for approximately 50% of 
hereditary breast cancers and 90% o f hereditary ovarian cancers 
(Ford & Easton, 1995; Easton et al., 1993).
Inheritance o f familial cancer syndromes usually follows an 
autosomal dominant mendelian pattern, as a tumour suppressor, 
BRCA1 is recessive at the cellular level because inactivation of 
both copies is required for tumourigenesis (Berchuck et al., 
1998a). It is now well established that the age-specific and 
lifetime risk o f developing ovarian cancer is predicted to be 
high for carriers o f the BRCA1 gene (Berchuck et al., 1998a).
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1.4. BRCA1 GENE
1.4.1. M olecular Genetics of the BRCA1 Gene
BRCA1 spans 100 kb on chromosome 17q21 (Bowcock et al., 
1993; Kelsell et al., 1993; Neuhausen et al., 1994) and contains 
24 exons. The 7.8 kb mRNA encodes a protein o f 1863 amino 
acids (Miki et al., 1994a). The largest BRCA1 exon is exon 11, 
which has a 3.4kb long cDNA. The structure o f BRCA1 is not 
strikingly homologous to other known molecules apart from the 
presence o f a ring zinc finger domain at the amino terminus of 
the protein (Saurin et al., 1996) and a granin consensus 
sequence (BRCA1 amino acids 1214-1223) (Jensen et al., 1996) 
(figure 1.1). The ring finger domain is being found in an 
increasing number o f proteins and might be involved in 
mediating protein-protein interactions. The functional 
importance o f this m otif is supported by the observation that it 
is highly conserved in other species (Bennett et al., 1995). 
Jensen et al. (1996) suggested that BRCA1 exhibits properties 
o f the 10 amino acid granin that is also conserved across 
species.
BRCA1 has also two “BRCT” repeats at the carboxyl terminus 
(Koonin et al., 1996; Callebaut & Mornon, 1997). The BRCT 
repeat is a poorly conserved domain found in a range of 
proteins many o f which are involved in either DNA repair or 
metabolism (Koonin et al., 1996; Callebaut & Mornon, 1997).
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1.4.2. Location of BRCA 1 Protein
There is a controversy about the sub-cellular location of 
BRCA1 protein. In normal cells, there is an agreement that 
BRCA1 is a nuclear protein (Chen et al., 1995; Aprelikova et 
a l , 1996; Shao et al., 1996; Wilson et al., 1997; Scully et al., 
1996; Chen Y. et al., 1996). However, there is a discussion 
about the location o f protein in tumour tissue. It has been 
reported (Chen et al., 1996) that BRCA1 is present in the 
cytoplasm o f cancer cells whereas Scully et al. (1996) have 
suggested that the protein still remains in the nucleus of these 
cells. Splice variants o f BRCA1 that lack either exon 11 or 
exons 9 and 10 have been described. It has been suggested that 
some splice variants may lose a nuclear localisation domain, 
which might explain the conflict between results obtained by 
various groups (Chen et al., 1996; Wilson et al., 1997).
On the other hand, it was suggested (Jensen et al., 1996; Steeg, 
1996) that BRCA 1 is a secreted protein which has a 10 amino 
acid granin m otif (granin is a member of secreted proteins), and 
its secretion is triggered by activation of cyclic AMP and 
induced by estradiol. It has also been reported that BRCA1 is 
present in the Golgi complex.
1.4.3 M olecular Organisation and Regulation of the BRCA 1 
Gene
Many tumours arising in patients with germline mutations 
display loss of heterozygosity (LOH), which uniform ly involves 
loss of the wild-type BRCA1 allele. It has been suggested that 
BRCA1 is a tumour suppressor gene. Furthermore, it has been
15
shown in cultured cells that expression o f BRCA 1 increases as 
cells move out o f G l into the S phase o f the cell cycle (Vaughn 
et al., 1996). In addition, BRCA1 antisense strategies using 
cultured cells resulted either in acceleration o f proliferation 
(Thompson et al., 1995) or cell transformation (Rao et a l ,  
1996), supporting the tumour-suppressive function of BRCA 1. 
BRCA1 has been shown to have a specific interaction with 
Rad51 protein (figure 1.1) mediated through a BRCA1 exon 11 
domain (Scully et al., 1997b). Rad51, in mammals, is involved 
with the homologous pairing of DNA during the process of 
recombination and the recombinational repair, supporting the 
proposition that BRCA1 is involved in DNA repair processes 
(Sung & Robberson, 1995). The interaction between these two 
proteins was first found from the observation o f similar staining 
patterns during S and M phases o f cell cycle (Scully et a l ,  
1996; Scully et al., 1997b). There are reports that BRCA1 
undergoes dramatic changes in phosphorylation and sub-nuclear 
localisation in response to DNA damage. The same changes in 
localisation apply to Rad51 suggesting that they may have a 
physiological interaction that is triggered by DNA damage 
(Scully et al., 1997a). Although the interaction seems to be 
specific, its functional basis is still not clear. It has been 
reported that the evidence for BRCA1 function in DNA repair 
suggests that it may not be a direct tumour suppressor gene but 
may be involved in the maintenance of genome integrity 
(Bertwistle & Ashworth, 1998).
The loss o f genome integrity, however, would lead to DNA 
damage and activation o f normal checkpoints on the cell
16
division involving, in particular, the p53 pathway (Kinzler & 
Vogelstein, 1976; Brugarolas & Jacks, 1997). P53 was 
identified in 1990 by Dr David Malkin and his colleagues 
(Malkin et al., 1990) and that it was mutated in 5 out o f 5 
families studied with the Li-Fraumeni syndrome. It is a tumour 
suppressor gene and mutated in a very wide variety of human 
cancers. It encodes a 53KD protein. It affects cell cycle in the 
G l phase of the cell cycle. It was hypothesised that loss o f the 
wild-type BRCA1 allele and p53 pathway are both required for 
tumourigenesis. There are two ways that this could occur 
(Kinzler & Vogelstein, 1976; Brugarolas & Jacks, 1997).
First, the loss of the wild type BRCA1 gene in a carrier o f a 
BRCA1 mutant might lead to a defect in DNA repair. DNA 
damage would result in the induction of p53, which mediates 
growth arrest or apoptosis. Loss o f the p53 pathway would 
reduce the growth-arrest allowing cell division. Growth with a 
failure o f the DNA repair pathway might lead to the activation 
of an oncogene and neoplasia.
Second, cells carrying a heterozygous mutation in BRCA1 might 
lose the p53 pathway. Loss o f the wild-type BRCA1 allele 
would then be driven by a main defect caused by loss o f p53 
function. Thus, failure o f a DNA repair mechanism might lead 
to the activation o f an oncogene and neoplasia (Bertwistle & 
Ashworth, 1998) (Figure 1.2).
Crook et al. has reported that in their study, p53 mutations have 
been found in one familial breast and three familial ovarian cancer 
patients. It has been also suggested that loss of BRCA1 function 
activates a genome guardian checkpoint which mediates the block to
17
cell cycle progression, suggesting that p53 may be such a checkpoint 
and that BRCA1 tumorigenesis may require not only the inheritance 
of a mutant germline BRCA1 allele, but also an acquired p53 
mutation.
Two separate promoters exist for BRCA1 , generating transcripts 
that differ in the first exon, which is a part o f the untranslated 
region (Xu et al., 1995). Both promoters contain oestrogen 
response elements, suggesting that BRCA1 may be involved in 
hormone signalling pathways (Xu et al., 1997b). Although 
evidence suggests that this may be an indirect and nonspecific 
effect, which is related to changes in the cell cycle rather than 
to interactions between BRCA1 and a control pathway 
(Spillman & Bowcock, 1996;; Marks et al., 1997; Gudas et al., 
1995).
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1.4.4. Molecular Pathologies in BRCA1 Gene:
BRCA1 is not mutated in sporadic Breast tumours and only 
rarely in sporadic ovarian cancers (Takahashi et al., 1996; 
Futreal et al., 1994; Merajver et al., 1995; Hosking et al., 1995; 
Foster et al., 1996). Mutations in the BRCA1 gene reported so 
far, disrupt the normal function o f the protein. In early reports, 
approximately 85% of the alterations in BRCA1 were either 
nonsense mutations in which a single nucleotide substitution 
produced a stop codon or frameshift mutations in which one or 
more nucleotides were deleted producing a stop codon 
somewhere downstream (Shattuck-Eidens et al., 1995; Couch & 
Weber, 1996). In either case the predicted result is production 
o f a smaller than usual BRCA1 protein. In these reports, 
missense mutations that only change a single amino acid formed 
about 10% o f BRCA1 mutations.
The recent reports show that the nonsense, frame-shift 
mutations and splice variants in the BRCA1 gene that produce 
short products are not as frequent as previously thought. (Breast 
cancer information Core http://www.nhgri.nih.gov/). Almost 
850 different mutations have been reported out o f nearly 4000 
entries and more than 500 (57%) of them have not been 
previously reported.
More than half o f those mutations (57%) are small insertions, 
deletions, nonsense mutations, splice variants and regulatory 
mutations that are predicted to affect the size and the molecular 
functions of the BRCA1 protein. Nearly, one third o f those 
mutations (29%) are missense mutations that change functions 
o f BRCA1 protein. Where missense mutations involve highly
20
conserved functional domains in BRCA1 it is likely they are 
deleterious. More than 10% of all entries in the database are 
identified as polymorphisms. The most frequently identified 
mutation to date is “ 185delAG” which is predicted to produce a 
short 39 amino acid peptide.
On the other hand, the frequency of these mutations, including 
nonsense mutations, small deletions and insertions, missense 
mutations occurring at crucial aminoacid positions within well 
conserved domains and mutations affecting splice sites is lower 
than expected from data, based on linkage analysis (Szabo & 
King MC., 1997). Some o f these mutations can be attributed to 
the major genomic rearrangements o f the BRCA1 gene, which 
escape most o f the current PCR-based mutation detection 
methods (Petrij-Bosch et al., 1997; Swensen et al., 1997; Puget 
eta l.,  1997).
It has been noted that various BRCA1 mutations may tend to 
result in the development of different cancers. It has been 
suggested that mutation in the carboxyl terminus o f the gene 
may result in a higher frequency of breast cancer, relative to 
ovarian cancer (Shattuck-Eidens et al., 1995; Gayther et al., 
1995b). On the other hand, mutations in the proximal amino end 
of the gene may result in a higher likelihood of developing 
ovarian cancer. Studies on phenotype/genotype correlation 
suggests that carboxyl terminal BRCA1 mutants effectively 
inhibit growth of ovarian, but not breast, cancer cells (Holt et 
al., 1996).
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1.5. MUTATIONS RESPONSIBLE FOR GENETIC 
ALTERATIONS
Mutation is the result o f any detectable change that affects 
DNA’s chemical or physical constitution, its replication, its 
phenotypic function, or the sequence of one or more DNA base 
pairs. I f  a mutant cell gives rise only to somatic cells, it cannot 
be passed to the next generation. This type o f mutation is called 
a somatic mutation. However, mutations in the germline can be 
transmitted to the next generation as the mutation is in both the 
somatic and the germ line cells. These kind o f mutations are 
called germline mutations.
1.5.1. Types of Mutations:
A change in the organisation o f a chromosome is called a 
chromosomal mutation or aberration. A mutation in a gene 
sequence is called gene mutation. These mutations can occur 
spontaneously or induced by the application of a mutagen. 
Mutations that result from treatment with mutagens are called 
induced mutations, naturally occurring mutations are 
spontaneous mutations. Gene mutations can involve any 
number of alterations of the DNA sequence o f the gene, 
including base-pair substitutions, and insertions or deletions of 
one or more base pairs.
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1.5.1.1. A base-pair substitution mutation:
It is a chance in a gene that one base pair is replaced by another 
base pair. There are two different ways that a base-pair 
substitution can occur: a transition mutation and a
transversion mutation.
A transition mutation is a specific type o f base-pair 
substitution mutation involving a change from one purine base 
pair to the other purine base pair. The four types o f transition 
mutations are: A to G, G to A, T to C, and G to T (Figure 1.3).
A transversion mutation is another specific type o f base-pair 
substitution mutation involving, a change from a purine base 
pair to a pyrimidine base pair. The four types of transversion 
mutations are: A to T, G to C, A to C, and G to T (Figure 1.3). 
Mutations can also be defined according to their effects on 
amino acid sequences in proteins.
Missense mutations: This is a base-pair substitution mutation 
in which a base-pair change in the DNA causes a change in an 
mRNA codon so that a different amino acid is inserted into the 
polypeptide in place o f the one specified by the wild type 
codon, resulting in an altered protein (figure 1.4).
Nonsense mutations: This is a base-pair change in DNA that 
results in a change o f an mRNA codon from one that specifies 
an amino acid to a chain-terminating codon (UAG, UAA, or 
UGA) (figure 1.4).
Neutral mutations: This base-pair substitution in a gene 
changes a codon in the mRNA such that the resulting amino 
acid produces no detectable change in the function of the 
protein translated from the message (Figure 1.5).
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Silent Mutations: This is also a kind of missense mutation in 
that a base pair change in a gene alters a codon in the mRNA 
such that the same amino acid is inserted in the protein (Figure 
1.5). The wobble hypothesis, proposed by Francis Crick 
(Crick, 1979), has shown that the base at the 5 ’ end of the 
anticodon is not as constrained as the other two bases. This 
feature allows for less exact base pairing so that the base at the 
5 ’ end of the anticodon can potentially pair with one of three 
different bases at the 3’ end of the codon. The protein, in this 
case, has wild-type function.
1.5.1.2. Point mutations:
Point mutations occur when only one nucleotide is deleted or 
inserted. It also occurs when a nucleotide substitutes to another 
nucleotides in the same position resulting in a missense 
mutation.
1.5.1.3. Frameshift mutations:
A frameshift mutation results from the addition or deletion of 
one or more base pairs in a gene (when only one base pair is 
involved, the frameshift mutation is also called a point 
mutation).
1.5.1.3.1. Deletions:
A deletion is a loss o f one or more base pairs in a gene. It shifts 
the mRNA’s reading frame by one or more bases so that 
incorrect amino acids are added to the polypeptide chain after 
the mutation sites. Often, deletions generate new codons
25
resulting in a stop codon, which may shorten the protein, or 
they result in readthrough of the normal stop codon, resulting in 
longer than normal proteins. In either case, deletions usually 
result in a non-functional or semi-functional protein (Figure 
1.6 ).
1.5.1.3.2 Insertions:
Insertion is a gain o f one or more base pairs in a gene that result 
in change to the reading frame of a gene from the site o f 
mutation onward. Like deletions, there are two possible 
outcomes from this change. Mutated mRNA can create either a 
short product, because the mutation would produce an 
unexpected stop codon, or a long product, because insertion 
would change the reading frame and when the translation 
reaches the original stop codon, it would no longer be 
recognised as such, and the translation process would continue 
beyond the end (figure 1.7).
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1.6 APPLICATIONS FOR MUTATION DETECTION 
AND SCREENING
There is no one technique, which is ideally suited for all 
mutation detection. All applications have advantages and 
disadvantages. Some are straightforward to perform and rapid 
but less sensitive than other techniques, whereas others have 
high sensitivity but are time consuming, labour intensive and 
less cost-effective. The choice of application can also be 
dependent on other factors, including the material to be 
analysed, whether it is genomic DNA or cDNA. Some available 
methods are detailed below.
• Single Strand Conformation Polymorphism Analysis 
(SSCP/SSCA)
•  Protein Truncation Test (PTT)
•  Heteroduplex Analysis (HA)
•  Chemical Cleavage M ismatch Analysis (CCM)
•  Denaturing Gradient Gel Electrophoresis (DDGE)
•  Nucleic Acid Sequencing
1.6.1. Single Strand Conformation Polymorphism Analysis 
(SSCP/SSCA):
Single strand conformation polymorphism analysis was 
originally described by Orita et al. (Orita et al., 1989a; Orita et 
al., 1989b). With this method, regions of DNA thought to 
contain mutations are amplified using the polymerase chain 
reaction (PCR), and rendered single-stranded by heating. The
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separated strands are then fractionated on a non-denaturing 
polyacrylamide gel or the mutation detection enhancement 
(MDE) gels under conditions that may resolve two molecules 
differing by a single base (figure 1.8). Because conformational 
changes and the consequent alterations in electrophoretic 
mobility cannot be predicted, separation using several different 
conditions may be required to detect all mutations. SSCP 
analysis can be best applied if  the products are 150-350 bp in 
length. It has been suggested that if  the product is under 200 bp, 
the detection rate will be maximised.
SSCP analysis is today being widely used, because it is 
technically easy and can be used in the screening of large 
numbers o f samples. It has been accepted that in 80%-100% of 
cases a single base change is sufficient to cause altered 
electrophoretic mobility, if  the product is 150-350 bp in length.
1.6.2. Protein Truncation Test (PTT):
The protein truncation test (PTT) is a mutation detection 
method that specifically detects mutations which lead to the 
premature termination o f mRNA translation and subsequent 
protein truncation. It detects mutations which lead to the 
shortened protein by producing an early stop codon: nonsense 
mutation where a single nucleotide substitution which produces 
a stop codon (TGA, TAA or TAG) and mRNA translation stops 
at the point o f mutation, frameshift mutation where one or 
more nucleotides are either inserted or deleted and if the 
number o f bases is not divisible by 3, a change in the reading 
frame will occur which will alter the remainder of the
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translation o f the mRNA, and frequently a stop codon is 
introduced prematurely.
PTT is carried out by amplification o f target DNA by PCR. This 
can be as long as 3kb, without introns. The upstream primer has 
a T7 promoter at its 5 ’ end and is added to a coupled in vitro 
transcription-translation system. For detection, a labelled amino 
acid is included during amplification, this is usually 
methionine, leucine or cysteine. The label can either be a
'■y r
radionucleotide such as [ S] which is visualised by 
autoradiography, or biotin which is detected by a colorimetric 
W estern blot employing a streptavidin-biotin-alkaline 
phosphatase complex. The polypeptides produced are separated 
by size using an SDS-PAGE gel. If  the only product visualised 
is full length, no truncating mutation is present. Truncating 
mutations result in shorter products, the size o f which gives the 
approximate position o f the mutation (Figure 1.9).
The most valuable advantage of PTT is that it allows the 
analysis o f large stretches of coding sequence, as long as 3kb. It 
only detects mutations that create a stop codon, therefore 
polymorphisms are not identified. It can only detect a mutation 
in a coding sequence thus it is suitable for analysis o f large 
exons. For genes with small exons, RNA extraction and cDNA 
preparation will be needed. It has been reported that PTT has a 
100% detection rate.
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DIAGRAM OF SSCP REACTION
SSCP
Homozygote A Heterozygote Homozygote B
Denature with Heat and Formamide
Native Gel Electrophoresis
Figure 1.8: Diagram of SSCP reaction: The SSCP analysis is 
dependent on conformational differences in single stranded DNA. 
Regions of DNA thought to contain mutations are amplified using 
the polymerase chain reaction (PCR), and rendered single-stranded 
by heating. The separated strands are then fractionated on a non­
denaturing polyacrylamide gel or mutation detection enhancement 
(MDE) gel.
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Figure 1.9: Protein Truncation Test (PTT). (MRCPath Self-help 
course, 1998-1999 Course Birmingham.
(http://209.185.131.251/cgi-bin/).
Forward primer.
5' 3'
TAATACGACTCACTATAGGGAGACCACCATGGAGAACAACTGTCTACAAACT
T7 promoter translation gene-pecific
initiation sequence
5' sequence
“h1
3' 5'
Reverse primer
a) The forward primer carries at its 5' end a T7 promoter, followed by a 
eukaryotic translation initiation sequence, which includes an ATG start 
codon.
Next is a gene-specific sequence designed so that the sequence amplified 
reads in-frame from the ATG.
Size
markers
Full
len g th
transcript
Truncated
transcripts
b) If the product is full length, no truncating mutation is present. 
Truncating mutations result in shorter products, the size o f which gives 
the approximate position o f the mutation.
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1.6.3. Heteroduplex Analysis (HA):
This technique can be used to identify point mutations or single 
base pair polymorphisms in heterozygous individuals. It takes 
advantage o f the fact that heteroduplex molecules containing 
single base pair mismatches can be separated under particular 
conditions o f gel electrophoresis from nearly identical 
molecules containing no mismatches (White et al., 1992). RNA 
or DNA from a potentially heterozygous individual is amplified 
by PCR and the products are run on non-denaturing mutation 
detection enhancement (MDE) or polyacrylamide gels. Hybrid 
molecules containing a mismatch, migrate more slowly than 
their corresponding homoduplexes. It has been shown that MDE 
gels have significantly greater ability than polyacrylamide gel 
to resolve and point mutations.
PCR products o f more than 500 bp in length are not suitable for 
single base pair mutation detection.
1.6.4. Chemical Cleavage Mismatch Analysis (CCM):
This was first described by Cotton et al. (1988). Mutation 
screening by the chemical cleavage method is based on the fact 
that mismatched cytosine (C) and thymidine (T) are much more 
reactive with the compounds hydroxylamine and osmium 
tetroxide, respectively, than Watson and Crick-paired cytosine 
and thymidine bases. In this protocol, an excess o f unlabeled 
target DNA is hybridised with labelled, wild type DNA probe 
and heteroduplexes are formed. One part is treated with 
hydroxylamine, which reacts with mismatched C bases, the 
other part is treated with osmium tetroxide, which reacts with
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mismatched T bases. The reactions are mixed with piperidine 
which cleaves the strands at the sites where hydroxylamine and 
osmium tetroxide react. Cleaved fragments are then 
electrophoresed and sized on polyacrylamide gels, identifying 
the point o f cleavage. Mismatched G and A bases will not be 
directly detected, but they are transposed to mismatched C and 
T bases respectively, by use of a probe o f the opposite sense for 
detection.
Although it was first described as a screen for point mutations, 
deletions and insertions can also be detected by this method. It 
has been claimed to have an almost 100% success rate for single 
base pair mutation detection.
1.6.5. Denaturing Gradient Gel Electrophoresis (DDGE):
Separation o f DNA fragments by denaturing gradient gel 
electrophoresis (DDGE) was first described by Fischer and 
Lerman (Fischer & Lerman, 1978). The separation principle of 
denaturing gradient gel electrophoresis is based on the melting 
behaviour o f the DNA double helix o f a given fragment. This 
melting behaviour is sequence dependent and generally occurs 
in discrete domains rather than at single bases. Strand 
separation at a domain in a DNA fragment is detected as a 
reduction in the mobility o f the fragment when it moves through 
an acrylamide gel containing a chemical denaturant gradient. 
Two double-stranded DNA fragments of the same size, but 
differing in sequence, melt at different points in a denaturing 
gradient and can be distinguished by differential migration.
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PCR products should be in the 100-800 bp range, however, 
more than two or three melting domains in a fragment would be 
the limitation for a successful result. It has been reported that 
between 90-100% o f all possible mutations in the area screened 
can be reliably detected using this method.
1.6.6. Nucleic Acid Sequencing:
Although nucleic acid sequencing became commonplace in 
studies o f molecular systems in the late-1970s, only stretches of 
DNA 15-20 base pairs in length had been sequenced. 
Breakthroughs in nucleic acid sequencing were published 
almost simultaneously by Maxam and Gilbert (Maxam & 
Gilbert, 1977) and Sanger et al. (Sanger et al., 1977).
Maxam and Gilbert, or chemical DNA sequencing relies on the 
use o f base-specific modification and cleavage reactions. In this 
method, a DNA fragment is electrophoretically separated into 
its two complementary strands, and each of them end labelled 
with [32P]. Sequencing was accomplished by dividing the target 
DNA into four sub samples and then treating the sub samples 
with a series o f base-specific chemical reagents that partially 
cleave the DNA. The radioactively labelled fragments from the 
four sub samples are then electrophoretically separated by size 
on a denaturing polyacrylamide gel and visualised by exposing 
the dried gel to an X-ray film to produce an autoradiograph. 
Sanger sequencing, or controlled interruption o f enzymatic 
DNA replication, uses dideoxynucleotide analogs in primer- 
directed DNA extension to produce discrete DNA fragments.
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The doubled-stranded DNA is first denatured to produce a 
single-stranded DNA.
Next, using a primer, the sample is divided into four sub 
samples, to each o f which is added the four deoxynucleotides 
and DNA polymerase. In addition, one of four 
dideoxynucleotide (ddNTP) is added to each o f the tubes. The 
primer has a free 3 ’-OH group on its deoxyribose, to which 
additional nucleotides can be attached. The DNA polymerase 
using the target DNA as a template extends the DNA sequence. 
At some point, the polymerisation is terminated because the 
ddNTP lacks a 3 ’-OH group. The radioactive fragments are then 
separated by denaturing polyacrylamide gel electrophoresis and 
visualised by autoradiography (figure 1.10).
Later on, another method, called cycle sequencing, was 
introduced. Cycle sequencing is based on the dideoxynucleotide 
chain-termination method o f Sanger et al., but utilizes a linear 
polymerase reaction to amplify labelled DNA that is 
complementary to the target DNA (Murray, 1989; Craxton, 
1991). In this method, first, a segment of the candidate gene is 
PCR amplified from the genomic DNA o f an affected 
individual. The PCR product is then subjected to multiple round 
of further amplification in a thermal cycler using a heat-stable 
DNA polymerase in the presence of different 
dideoxynucleotides and a radiolabeled primer. The resulting
32[ P]-labeled sequence reaction products are fractionated on a 
denaturing polyacrylamide gel and visualised by 
autoradiography.
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5 ' - G T T T T C C C A G T C A C G A C A A T C A G G C T T A A A  - 3'  
3 ' - C A A A A G G G T C A G T G C T G T T  A G T C C G A A T T T  - 5 '
D en atu re D N A  to p ro d u ce  
s in g le -stra n d ed  tem plate  
(on ly  o n e  strand sh o w n )
3 ' - C A A A A G G G T C A G T G C T G T T A G T C C G A A T T T  - 5 '
A d d  p rim er an d  an n eal 
5 ' - G T T T T C C C A G T C A C G A C 3'
5 ' - G T T T T C C C A G T  CA CG A C 
3 ' - C A A A A G G G T C A G T G C T G ‘ A G T C C G A A T T T - 5 '
D iv id e  in to  four sa m p le s , each  w ith  dA T P, dC T P, dG T P, dTT P  
(at least o n e  d N T P  rad io a ctiv e ly  lab eled ) a n d  D N A  p o ly m e ra se
r v
d d A T P  d d C T P
pr imer+A primer+A A TC
primer+A A p r i me r+AATCAGGC
p ri me r+AATCA |
p r im er +A A T C A G G C T T A  
p r i m e r + A AT C A GG C T T AA  
o r im er +A A T C A G G C T T A A A
T
d d G T P
le r +AAT CAG
l er +AAT CAG G
T
d d T T P
pr i mer+AAT
primer-i-A A T C AG G C  T
primer+A A T C AG G C  T T
Separate fragm en ts by e lectrop h oresi 
and v isu a liz e  bv a u to rad iograp h v
Figure 1.10: Sanger (enzym atic) sequencing. The DNA
replication, uses d ideoxynucleot ide  analogs in primer-directed 
DNA extension to produce discrete DN A  fragments .(David  et 
al., 1996)
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Cycle sequencing is an efficient method to screen for mutations 
compared with those methods, mentioned above. Fragments up 
to 300 bp in length can be searched for mutations. However, 
recent development in sequencing have given an opportunity to 
search for mutations more quickly and more cost-effectively. 
This new technique is known as automated sequencing. There 
are a number o f types of automated sequencing protocols, but 
the most common is Sanger sequencing with fluorescently 
labeled DNA fragments. The method involves the synthesis o f a 
DNA strand by a DNA polymerase, using a single stranded 
DNA template. The synthesis is initiated at the site where a 
primer anneals to the template. Elongation is facilitated from 
the 3 ’ end of the annealed primer by a DNA polymerase in the 
presence of dNTPs and is terminated by the incorporation o f a 
ddNTP, which will not support continued DNA elongation. 
Since each ddNTPs are tagged with a different fluorescent label, 
(G=black, T=red, O B lu e  and A=Green) the fluorescent 
sequencing instrument recognises the distinct label colours to 
give complete sequencing information. These fragments, which 
are invisible with the naked eye, are detected during the 
electrophoresis with the use of a tunable laser. The laser is 
stationary with respect to the electrophoresis apparatus, and 
fragments are recorded as they pass a single point. The system 
does not need autoradiography or manual recording of results. 
Instead, the sequence is recorded and analysed directly in a 
computer and can be printed out for further analysis.
The maintenance of this system is expensive, however, it can be 
very cost effective in the long run. It is also much quicker and
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more reliable in comparison to manual sequencing that may 
take a week to have a result.
1.7. AIMS OF THIS STUDY
The aim o f this project was to identify and characterise 
mutations in BRCA1 in patients from the West o f Scotland with 
ovarian cancer. Patients, who had one or more first or second 
degree relatives with breast or ovarian cancers, would be 
selected. W ell-established mutation screening techniques such 
as single strand conformational polymorphism analysis (SSCP) 
and the protein truncation test (PTT) would be employed. 
Suspected mutations will be confirmed by automated DNA 
sequencing.
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CHAPTER II
MATERIALS AND METHODS
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2.1. PATIENTS
Forty-eight ovarian and breast-ovarian cancer patients with 
between one and six affected first or second degree relatives 
have been selected from patients attending the cancer clinic of 
the department o f Medical genetics (table 2.1a,b). The range of 
onset for these patients is between 22 and 78 years of age and 
the median age o f onset is 49.8 years. All those patients were 
screened for BRCA 1 gene using DNA as a template by SSCP 
and exon 11 was also screened by PTT.
2.2. EXTRACTION OF DNA FROM PERIPHERAL 
BLOOD CELLS
DNA from peripheral lymphocytes was isolated according to 
the method described in the PureGene Kit (REF). 10ml o f whole 
blood was added to 30ml ice-cold red cell lysis solution 
(155mM Ammonium Chloride, lOmM Potassium Hydrogen 
Carbonate, ImM  EDTA). The mixture was incubated at room 
temperature for 15-20 minutes and inverted occasionally to mix. 
It was then centrifuged at 2000 r.p.m. for 5-10 minutes at room 
temperature. The supernatant was discarded and 10 ml of cell 
lysis solution (25mM EDTA, 2% SDS) were added to the pellet 
to fully lyse the cells. When the solution was homogenous, (and 
now stable at room temperature for at least 18 months) 3.5ml 
protein precipitation solution (10M Ammonium Acetate) was 
added and the mixture vortexed vigorously. It was then 
centrifuged at 3000 r.p.m. for 20 minutes at room temperature 
to pellet the proteins. The supernatant was transferred to a clean
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tube containing 10ml isopropanol. It was mixed thoroughly by 
inversion to form a DNA precipitate. DNA was spooled out by 
using a sealed Pasteur pipette and washed in 70% ethanol. It 
was then air dried and dissolved in an appropriate volume (100- 
800///) o f TE buffer (lOmM Tris/HCl pH 8.0, ImM EDTA) and 
stored at -20°C until required.
2.3. DESIGN OF OLIGONUCLEOTIDE PRIMERS
The oligonucleotides used in this study for SSCP analysis have 
been published by Friedman et al. (Friedman et al., 1994) and 
those for PTT have been published by Hogervorst et al. 
(Hogervorst et al., 1995). Oligonucleotide primers were
generally designed in the range of 18-24 bases except for those 
that were used for PTT analysis (56-58 bases). In order to 
screen the entire BRCA1 gene, there were 46 sets o f primers 
(table 2.2-2.3-2.4) for SSCP analysis and to screen exon 11, 
there were 3 sets o f PTT primers (table 2.5). Two 
oligonucleotide primers were produced for each polymerase 
chain reaction (PCR). The forward primer (F) was 
complementary to the sense strand and the reverse primer (R) 
was complementary to the antisense strand. For PTT, the 
forward primer contained a T7 primer with a promoter sequence 
and a sequence for the initiation of translation (Hogervorst et 
al., 1995).
All the oligonucleotides were synthesised on an APPLIED 
BIOSYSTEM (ABI) 391 DNA SYNTHESISER. Ammonium 
hydroxide was used to elute the primers from the solid support
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and deprotection was carried out at 55°C for 12-16 hours. In 
order to purify the deprotected oligonucleotides, a 250fil primer 
aliquot was taken out and left in the fume hood to allow rapid 
evaporation o f ammonia then left at -20°C until required. The 
bulk o f the primers were stored in their ammonia solutions at - 
20°C until required.
Patient 
Sample No:
Ovarian 
Cancer (Age)
Breast
Cancer
(Age)
Other
Cancers
Family Members 
(Num/Mean 
Age)
1 41 — 1/50
2 39 41 — 2/43
3 60 45 — 3/51
4 43 56 — 3/64
5 42 42 — 4/42
6 66 66 — 2/62
7 60 — — 1/35
8 35 40 - - 3/40
9 67 — — 1/65
10 65 — - - 1/67
11 47 — — 1/56
12 60 - - — 1/70
13 32 — — 1/60
14 66 48 — 2/59
15 74 — — 2/64
16 54 66 — 1/54
17 22 — — 1/32
18 39 32 — 6/46
19 56 — — 4/43
20 62 — - - 4/43
21 42 39 — 4/43
22 44 45 — 2/37
Table 2.1a: Characteristic of ovarian cancer patients
(patients no, 1-22) who have been tested for BRCA1 mutations 
in this study.
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Patient 
Sample No:
Ovarian 
Cancer (Age)
Breast
Cancer
(Age)
Other
Cancers
Family
Members
(Num/Mean
Age)
23 45 33 — 2/40
24 54 58 — 1/54
25 45 — — 1/30
26 56 43 — 1/40
27 69 - - — 1/40
28 48 46 — 5/47
28 78 61 - - 4/53
30 63 59 63 2/75
31 44 — — 3/39
32 63 — — 2/67
33 66 — — 2/51
34 40 — — 1/47
35 60 — 59 1/63
36 43 — — 2/55
37 24 — — 1/60
38 49 — — 3/74
39 52 — — 4/81
40 25 — — 1/70
41 50 — — 2/52
42 49 — - 2/46
43 28 — — 3/56
44 26 - - — 2/35
45 38 55 — 2/45
46 59 — — 5/42
47 48 - - — 3/42
48 56 48 — 1/53
Table 2.1b: Characteristic of ovarian cancer patients
(patients no, 23-48) who have been tested for BRCA1 mutations 
in this study.
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2.4. THE POLYMERASE CHAIN REACTION 
(PCR) USING GENOMIC DNA AS A TEMPLATE
2.4.1. Polymerase Chain Reaction for SSCP
Polymerase chain reactions were performed by using a PCR 
Beads “ready-to-go” kit (Amersham Pharmacia Biotech). In this 
kit, dried PCR Beads were provided that were stable at room 
temperature and each bead contained all o f the necessary 
reagents for performing a 25fil PCR amplification reaction. 
Beads were pre-dispensed in 0.5ml thin-walled tubes.
Each reaction contained 1.5 units o f taq DNA polymerase, 
lOmM Tris-HCl (ph 9.0 at room temperature), 50mM KC1, 
1.5mM MgCl2, 200//M of each dNTP, 30-50pmol o f each 
primer and 0.1//g genomic DNA. Double distilled water was 
used to bring the volume to 25fil. The concentration of primers 
and DNA was optimized to get the best possible PCR result.
The cycles of PCRs were generally carried out as follows; two 
minutes at 95°C for one cycle (initial denaturation) followed by 
one minute at 95°C (denaturation), one minute at 58°C (primer 
annealing) and one minute at 72°C (primer extension) for 30 
cycles. The final extension was 7 minutes at 72°C for one cycle 
(table 2.6).
INITIAL
DEANTURATION DENATURATION ANEALING EXTENTION
FINAL
EXENSION
95°C, 2 MIN 95°C, 1 MIN 58°C, 1 MIN 72°C, 1 MIN
72°C, 7 
MIN
1 CYCLE 30 CYCLES 30 CYCLES 30 CYCLES 1 CYCLE
Table 2.6: PCR conditions for SSCP
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PCR products were visualized by 1% agarose gel analysis, 
ethidium bromide staining and transillumination using UV light.
2.4.2. Polymerase Chain Reaction for PTT
Polymerase chain reactions were performed by using a PCR 
Beads “ready-to-go” kit (Amersham Pharmacia Biotech). Total 
reaction volume was designed to be 50///. Therefore two PCR 
beads were used in one 0.5ml thin-walled tube.
Each reaction contained 3 units o f taq DNA polymerase, 20 mM 
Tris-HCl (ph 9.0 at room temperature), lOOmM KC1, 1.5mM 
MgCl2, 400//M o f each dNTP, 60-100pmol o f each primer and 
0.2//g genomic DNA. The ddH20  was used to bring the volume 
to 50///. The concentration o f primers or DNA was optimized to 
produce the best possible PCR result.
The PCR conditions were set as follows; two minutes at 95°C 
for one cycle (initial denaturing) followed by one minute at 
95°C (denaturation), one minute at 57°C (primer annealing) and 
two minute at 72°C (primer extension) for 35 cycles. The final 
extension was six minutes at 72°C for one cycle (table 2.7). 
PCR products were visualized by 1% agarose gel 
electrophoresis, ethidium bromide staining and 
transillumination using a UV light.
INITIAL
DEANTURATION DENATURATION ANEALING EXTENTION
FINAL
EXENSION
95°C, 2 MIN 95°C, 1 MIN 57°C, 1 MIN 72°C, 2 MIN
72°C, 6 
MIN
1 CYCLE 35 CYCLES 35 CYCLES 35 CYCLES 1 CYCLE
Table 2.7: PCR conditions for PTT
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2.5. IDENTIFICATION OF PCR PRODUCTS
Products were visualized by mixing 5jul o f PCR product with 
2/i/ o f loading mix (0.03% bromophenol blue, 0.03% xylene 
cyanol, 0.4% Orange G, lOmM Tris-HCl (pH 7.5) 15% FicolKD 
400 (Promega cat no. G1741) and loading on a 1% agarose gel 
containing ethidium bromide. A 1% agarose gel was prepared 
by adding 0.3-0.6g agarose powder (GIBCO BRL life 
technologies cat no. 15510-027) in 30-60ml lxTAE buffer 
(depending on the size of the gel). The mixture was boiled and 
cooled down to 60°C. Ethidium bromide (4/i/ from lOmg/ml. 
Sigma cat no. E1510) was added to the solution and the gel 
poured into a gel tray. The samples were loaded on the gel and 
electrophoresis at a constant 100 volts for 30 minutes. The 
results were then visualized using a standard UV 
transilluminator (Fotodyne, UV-transilluminator) and printed 
using a gel documentation (UVP Imagestor 5000) system.
2.6. PURIFICATION OF PCR PRODUCTS
At the end o f the PCR, the amplified DNA was purified by 
removing the excess primers, dNTPs, and salts using different 
techniques as follows.
2.6.1. GFX™  PCR DNA and Gel Band Purification Kit
A GFX DNA purification kit uses a chaotropic agent that 
denatures protein, dissolves agarose and promotes the binding 
o f double-stranded DNA to a glass fiber matrix. This kit was 
used to clean double-stranded DNA o f over 100 bp in size.
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Capture buffer (buffered acetate and chaotrope), wash buffer 
(Tris-EDTA buffer and 48ml 80% ethanol), GFX™ columns 
(microspin columns pre-packed with a glass fiber matrix), and 
collection tubes (2ml capless microcentrifuge tubes) were 
supplied with the kit. The maximum volume o f PCR product 
that could be processed with it was 100///.
For the cleaning procedure, each GFX™ column was placed in 
a collection tube. 500/// capture buffer was added to the GFX™ 
column and the mineral oil-free PCR product was mixed into 
the solution by pipetting the sample up and down 4-6 times. The 
mixture was then centrifuged in a microcentrifuge at 12000 
r.p.m. for 30 seconds. The residue was discarded from the 
collection tube and the GFX™ column was replaced into it. 
500/// o f wash buffer was added in to the column and 
centrifuged in a microcentrifuge at 12000 r.p.m. for 30 seconds. 
The collection tube was discarded and the GFX™ column 
transferred to a fresh 1.5ml microcentrifuge tube. The required 
amount o f double-distilled water (25-50///) was directly applied 
to the top of the glass fiber matrix in the GFX™ column 
without touching it. The concentration of the final product 
could be produced at this stage by adding less or more ddH20 . 
After incubating the sample at room temperature for one 
minute, a final centrifuge stage was carried out at 12000 r.p.m. 
for one minute. Recovered DNA was then collected from the 
microcentrifuge tube and stored for further usage.
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2.6.2. Isopropanol Precipitation of PCR Products
This method was used to remove excess dNTPs, salts and 
primers from PCR products for PTT analysis. Mineral oil-free 
PCR product was added to one volume o f 4M ammonium 
acetate and two volumes o f isopropanol into a 1.5ml 
microcentrifuge tube and left on ice for 10 minutes. The 
mixture was then centrifuged at 12000 r.p.m. for 20 minutes. 
The supernatant was discarded and the DNA pellet was twice 
washed in 70% ethanol and briefly centrifuged. After discarding 
the ethanol, the pellet was air-dried and dissolved in an 
appropriate amount o f Rnase-free (DEPC treated) water for 
further usage.
2.7. METHODS FOR MUTATION DETECTION
2.7.1 Mutation Detection by Single Strand Conformational 
Polymorphism Analysis (SSCP)
This technique allows the detection of single base changes in 
short DNA fragments, preferably under 300 bp, based on 
mobility differences of single stranded molecules. DNA 
fragments differing in sequence by as little as 1 bp will have 
different three-dimensional structure due to the alteration of the 
intra molecular interactions. DNA fragments with different 
three-dimensional structures may move at a different rate to 
each other when electrophoresis through mutation detection gels
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such as non-denaturing polyacrylamide or a mutation detection 
enhancement (MDE™) gels.
SSCP analysis was used to screen all BRCA1 exons 1 to 24. All 
the BRCA1 genes thought to contain mutations were amplified 
by using polymerase chain reaction as described before. PCR 
products were then heated to generate single strands and 
fractionated on MDE™ gels. Silver staining was used for 
visualizing and detecting the product.
2.7.1.1. Gel Preparation and Pouring
The “Protean®II xi Cell” sequencing gel apparatus (Bio-Rad cat 
no. 165-1815) with 0.5mm spacers and comb was used for 
mutation detection of PCR products.
The 20cm X 20cm glass back plate and 16cm X 20cm glass 
front plate were cleaned by detergent, then washed and dried 
with ethanol. Dust and dirt free plates were assembled 
according to the m anufacturer’s instructions. The bottom of the 
plates were sealed using the sealing apparatus.
The gel was prepared using MDE™ gel solution (FMC 
Bioproducts, cat no. 50620) as follows: 10ml MDE™ gel 
solution, 4.8ml 5X TBE buffer, 2ml glycerol and 23.2ml 
distilled water were mixed. Then 50/// TEMED (N,N ,N’,N ’- 
Tetram ethyl-ethylenediamine, Sigma cat no. T-8133) and 
freshly prepared 10% ammonium per sulphate (APS) were 
added to the mixture and mixed well. The mixture was then 
poured immediately between two glass plates and the 20 well 
comb was inserted. The gel was allowed to polymerase for one
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hour. The sealing apparatus and the well forming comb were 
removed after the gel was set.
2.7.1.2 Preparation of the samples
4/il o f PCR was added to 6/il o f SSCP loading mix (95% 
formamide, lOmM sodium hydroxide, 0.5% bromophenol blue 
and 0.05% xylene cyanol) and heated for 5 minutes at 95°C. 
The sample was then cooled on ice for at least 2 minutes and 
5fil o f sample was loaded on to the MDE™ gel.
2.7.1.3 Running conditions of the gel
The gel was placed into the gel tank and sealed. The buffer 
chambers were filled with 0.6X TBE buffer and the wells were 
washed with buffer. The samples were then loaded on to the gel 
and electrophoresis was carried out at 4°C for 16-20 hours at a 
constant 140 volts.
2.7.1.4 Silver staining of the gel
Following electrophoresis, the gel was removed from the glass 
plates and placed in a staining dish. The gel was then fixed in a 
fixation solution (10% ethanol, 0.5% acetic acid) for 10 minutes 
at room temperature. The fixation solution was poured out and 
the gel was stained with cold 0.1% silver nitrate solution for 15 
minutes (Sigma cat no. S-6506) followed by twice rinsing with 
distilled water. The gel was then developed with a solution o f 
1.5% NaOH and 0.1% formaldehyde (both made from 10X 
stock) for 20 minutes (or until bands were clearly visible) at 
room temperature. After pouring the developing solution, the
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gel was fixed with a solution o f 0.75% N aC 0 3 (made from 10X 
stock) for 10 minutes. The gel was then covered by a sheet of 
plastic paper and its image recorded.
2.7.2 Mutation Detection by Protein Truncation Test
The protein truncation test (PTT) is method for detecting 
nonsense or frameshift mutations that create a stop codon and 
eventually truncated proteins. In this study, PTT has been 
performed for exon 11 by 3 overlapping segments because only 
genomic DNA was available. In this protocol, PCR was 
performed using forward primers containing the T7 promoter 
and a eukaryotic translation initiation sequence (Table2.5). 
Protein products were sysnthesised by using the TNT® Lysate 
Coupled Transcription/Translation System (Promega cat no. 
L4610).
2.7.2.1 Preparation of the forward primer with T7 promoter 
and target DNA
Because o f the absence of T7 promoter and translation initiation 
sequences for the target DNA segments, they had to be added to 
the 5 ’ end o f the forward primer to generate PCR products 
suitable for PTT analysis. The T7 promoter and initiation 
sequences, published by Hogervorst et a/.(Hogervorst et al.9 
1995) are presented below:
GCTAATACGACTCACTATAGGAACAGACCACCATGG 
As previously described, a 50/i/ PCR reaction was performed 
using a forward primer containing the T7 promoter and 
translation initiation sequences at the 5 ’ end. After confirming
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the size and the quality o f the product produced, PCR products 
were purified using isopropanol precipitation as described 
section 2.6.2.
2.7.2.2 TNT® Lysate Coupled Transcription/Translation  
System
The kit used in this experiment allowed translation and 
transcription in one Rnase-free reaction tube. All experiments 
were employed at 1/2 scale o f m anufacturer’s instructions to 
save material. 35S-methionine was used in this procedure as the 
radioactive material. The reactions were carried out as follows: 
12.5/// TNT® Lysate, 1 /// TNT® reaction buffer, 0.5/i/ TNT®
3 5RNA polymerase, 0.5/i/ amino acid minus methionine, 2/i/ S- 
methionine, 0.5/i/ RNasin (ribonuclease inhibitor 40u//i/), and 
8/i/ DNA in DEPC treated water. This mixture was then 
incubated at 30°C for 60-120 minutes.
2.7.2.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE was carried out using a Protean®II xi Cell kit. The 
apparatus was assembled according to the m anufacturer’s 
instruction. The SDS-PAGE was composed o f two different 
sections, stacking and separation gel. A 16cm separating gel 
which was 8.5%-17.5% depending on the size of translated 
product and containing separating gel buffer (18.17g Tris base 
and 4ml 10% Sodium Dodecyl Sulphate) was made by mixing 
the reagents shown in table 2.8, without forming air bubbles. 
The gel was then poured into the space between glass plates, 
leaving 4cm for the stacking gel.
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4cm
16cm
n  Stacking Gel (5%)
Separating Gel
(8.5-17.5%)
Figure 2.1. Schematic diagram of SDS-PAGE.
The gel was overlaid with 0.1% SDS solution to ensure a flat 
surface. After the gel was set, the SDS was washed off with 
water. A 4cm stacking gel which was always 5% in 
concentration (table 2.9), contained stacking gel buffer (6.06g 
Tris base and 4ml 10% SDS) was then made by mixing the 
reagents shown table 2.9, taking care not to form air bubbles.
COMPONENTS 8.5% 10% 12.5% 15% 17.5%
ddH20 16.85ml 14.95ml 11.85ml 8.7ml 5.6ml
Acrylamide 
Sol. 30%
10.65ml 12.55ml 15.65ml 18.8ml 21.9ml
Separating 
gel buffer
9.5ml 9.5ml 9.5ml 9.5ml 9.5ml
10% APS 560/i/ 560/// 560/// 560/// 560///
TEMED 25/// 25/// 25/// 25/// 25///
Table 2.8: Formulation of the SDS-Polyacrylamide
separating gel
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COMPONENT VOLUME
ddH20 5.0ml
Acrylamide Sol. 30% 2.22ml
Stacking gel buffer 1.5ml
10% APS 140///
TEMED 25/ul
Table 2.9: Formulation of the stacking gel (5% acrylamide)
The stacking gel was then poured onto the top o f the separating 
gel. A 1mm comb was inserted and the gel allowed to set. The 
apparatus was assembled and the gel tank was filled with IX 
SDS polyacrylamide running buffer (made from 10X stock, 30g 
Tris base, 144g glycine and 100ml 10% SDS).
2.7.2.4 Sample preparation
A 5jul aliquot from the transcription/translation reaction was 
diluted with 20/// o f SDS sample buffer (2.0ml glycerol, 2.0ml 
10% SDS, 0.25mg bromophenol blue, 2.5ml stacking gel 4X 
buffer, 0.5ml P-mercaptoethanol, and ddH 20 to a final volume 
o f 10ml), and mixed well. The mixture was then boiled for 3 
minutes to denature the protein. The remainder o f the 
transcription/translation product was stored at -20°C for future 
usage. The sample was then loaded (5-7///) on to the gel and run 
for 5-6 hours at constant 350 volts. In order to determine the
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size o f the product, 5jul o f the standard protein size marker 
(Rainbow marker, Amersham) was also loaded on to the gel.
2.7.2.5 Visualising the product
After the electrophoresis was finished, the gel was transferred 
to a staining tray and fixed for 20 minutes (the fixation solution 
was isopropanol, water and acetic acid in the proportions of 
25:65:10 respectively). The fixing solution was poured out and 
the gel was soaked in an amplify solution (Amersham cat no. 
NAMP 100) for 20 minutes. The gel was then transferred to a 
3mm Whatman paper, covered with Saran Wrap and dried in the 
vacuum dryer at 60°C for 45-60 minutes. The gel was then 
exposed for 2-4 days to X-ray film and the film developed 
according to the manufacturer’s instruction.
2.7.3. Expand Long Template PCR analysis
This analysis was employed to analyse DNA fragment that were 
too large for conventional PCR. It allows genomic DNA 
fragments o f up to 27 kb to be amplified.
Polymerase chain reaction was performed by using Expand® 
Long Template PCR system (Roche® cat no: 1-681-834). This 
system was composed o f an enzyme mix, containing a 
thermostable Taq DNA polymerase and a proofreading 
polymerase.
Each reaction contained 0.75pl o f enzyme mixture, 17.5 mM 
M gCl2, 350pl, 300nM of each primer and 500ng o f genomic 
DNA (Table 2.11). The forward and reverse primers, 5 ’- 
CCATACACATTTGGCTCAGGGTTACCGAAGAGGG-3’
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5 ’TTCGCAGGTCCTCAAGGGCAGAAGAGTCAC-3 ’ 
respectively were published by Payne et al. (2000). The PCR 
conditions were set as follows; two minutes at 93°C for one 
cycle (initial denaturing) followed by ten seconds at 93°C 
(denaturation), 30 seconds at 65°C (primer annealing) and eight 
minutes at 68°C (primer extension) for 30 cycles. The final 
extension was seven minutes at 72°C for one cycle (table 2.10).
INITIAL
DEANTURATION DENATURATION ANEALING EXTENTION
FINAL
EXENSION
93°C, 2 MIN 93°C, 10 s 65°C ,30 s 68°C, 8 MIN 68°C, 7 MIN
1 CYCLE 30 CYCLES 30 CYCLES 30 CYCLES 1 CYCLE
Table 2.10: PCR conditions for Expand long template PCR  
analysis.
The products were visualized by 0.7% agarose gel electrophoresis, 
ethidium bromide staining and transillumination using UV light.
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2.7.4. Nucleic Acid Sequencing
The samples, which gave positive screening results, were 
subjected to sequencing o f the PCR products from the 
corresponding DNA segment(s) to detect any sequence 
alterations. Automated sequencing of the PCR products was 
carried out using the “Thermo sequenase II dye terminator cycle 
sequencing premix kit” (Amersham cat no. US80975).
2.7.4.1. Preparation of sequencing reaction
A 25/// PCR reaction o f DNA was carried out as described in 
section 2.4.1. 4/// o f PCR product was resolved in a 1% agarose 
gel to check for quality and quantity o f PCR product. It was 
then purified using the GFX™ DNA purification kit as 
described in section 2.6.1. The purified PCR product was used 
for cycle sequencing and carried out as follows:
For the reaction, 15/// o f DNA template (diluted in ddH20  to 
80-800fmol) was mixed with ljul o f one of the initial primers set 
(5//M forward or reverse) and 4jul o f Thermo sequenase II 
reagent premix. The cycling program for sequencing was 
carried out as follows:
Two minutes at 96°C for one cycle (initial denaturing) followed 
by 30 seconds at 96°C (denaturation), 15 seconds at 50°C 
(primer annealing) and four minute at 60°C (primer extension) 
for 30 cycles.
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2.7.4.2. Purification of the product
At the end o f the thermal cycling, the 20/// o f product was 
removed and 2/// o f Sodium acetate/EDTA buffer and 60/// of 
100% cold (-20°C) ethanol was added. The sample was then 
vortexed and placed on ice for 15 minutes to precipitate the 
DNA. The sample was then centrifuged at 12000 r.p.m. for 20 
minutes at room temperature. The supernatant was poured off 
and the pellet was washed with 350/// o f cold (-20°C) 70% 
ethanol. It was then vortexed and centrifuged again at 12000 
r.p.m. for 3 minutes at room temperature. The supernatant was 
removed and the sample was air-dried.
2.7.4.3. Preparation of the sequencing gel
A 7.5% sequencing gel was prepared as follows:
18g urea was mixed with 18.5ml of ddH20 , 10ml 5X TBE 
buffer and 7.5 ml 50% long ranger gel solution (Flowgen). The 
mixture was warmed to 55°C to dissolve the urea. The mixture 
was then cooled o ff before the addition of 250/// o f 10% APS 
and 35/// TEMED.
Prior to pouring the gel, the glass plates were cleaned 
thoroughly and assembled as instructed in the ABI manual. The 
gel was then poured into the glass plates without forming 
bubbles and the flat comb was inserted. The gel was left for at 
least two hours to set.
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2.7.4.4. The running of the sequencing reaction on the 
automated sequencer
After the gel was set, the plates were placed in the ABI Prism 
373 automated sequencing machine following the instruction 
manual. A “plate check” procedure was performed to ensure 
that the plates were dirt free where the laser scanned. If  such 
artefacts were observed, the area was cleaned with a tissue until 
the scanned area was totally clean. The flat comb was removed 
and the 24 well comb was inserted. The gel was then pre-run in 
the IX TBE buffer for 10 minutes. 4/ul o f gel loading mix was 
added to the air-dried pellet. The sample was heated to 70°C for 
3 minutes and placed on ice. The sample was then loaded on to 
the gel.
2.7.4.5. Analysis of the result
The result obtained from each well were analysed on the 
Macintosh computer attached to the PRISM 373 DNA system, 
using the 373A software (ABI). The sequencer, which has a 
fluorescence detection system, sent the collected data to the 
computer. The computer processed the data and presented it as a 
chromatogram with four coloured peaks (G=black, T=red, 
C=Blue and A=Green). Heterozygosity was represented by two 
superimposed peaks. Thus, the computer could not call the base 
and gave it the designation “N ”.
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CHAPTER III
RESULTS
70
3.1. THE STRATEGY FOR AMPLIFICATION OF 
THE BRCA1 CODING SEQUENCE:
The entire BRCA1 coding sequence was amplified using 
genomic DNA. For this purpose, 47 sets o f primers for SSCP 
analysis (tables 2.2, 2.3, 2.4) and 3 sets o f primers (table 2.5) 
for PTT were employed for PCR amplification.
3.1.1. Amplification of the BRCA1 Gene Using Genomic 
DNA for SSCP Analysis
Because of the nature o f the BRCA1 gene, each exon could be 
covered by one set of primers giving sizes between 200 bp and 
375 bp, except exon 11. Its size is almost 3.4 kb, and it was 
amplified by 24 sets o f primers giving sizes between 200 bp and 
400 bp.
The optim isation of each PCR reaction was carried out 
according to the subject DNA size, primers size and G-C 
contents. The PCR reaction employed for SSCP is described in 
section 2.4.1. The amplified product was always 
electrophoresed in a 1% agarose gel to check the integrity of the 
PCR product. An example o f amplified product from patients 
DNA using primer set 1 IN is shown in figure 3.2.
3.1.2. Am plification of the BRCA1 Gene Using Genomic 
DNA for PTT
Am plification of exon 11 of the BRCA1 gene was carried out by 
three overlapping fragments, using primers described in table 
2.5 and genomic DNA as template.
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All forward primers contained a T7 promoter  and eukaryotic 
transla tion initiation sequence in order to generate  a PCR 
product  suitable  for PTT analysis. The amplified product  was 
always e lectrophoresed  in a 1% agarose gel to check the 
integri ty o f  the PCR product  and examples are shown in figures 
3.3-5.
k h
S O O h n
L S-l S-2 S-3
7 0 9  h n
Figure 3.2: PC R -am plified p roduct for SSCP analysis, using 
genom ic DNA as a tem plate. L= 100 bp DNA marker  (1 kb 
and 500 bp bands are indicated),  S - l ,  2,3 are patients DNA.
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P rim er
Figure 3.3: PCR-arnplified p roduct for PTT analysis from 
fragm ent-1 using genomic DNA as a tem plate. L= 100 bp
DNA marker (1 kb and 500 bp bands are indicated), C= 
negative control and S= PCR product  from patient  (1333 bp)
P rim er
Figure 3.4: PC R -am plified p roduct for PTT analysis from  
fragm ent-2  using genomic DNA as a tem plate. L= 100 bp
DNA marker  (1 kb and 500 bp bands are indicated), C= 
negative control and S= PCR product  from patient  (1463 bp)
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L C S
Figure 3.5: PC R -am plified p roduct for PTT analysis from 
fragm ent-3 using genomic DNA as a tem plate. L= 100 bp
DNA marker  (1 kb and 500 bp bands are indicated), C= 
negative control and S= PCR product  from patient  (1123 bp).
3.2. THE STRATEGY FOR DETECTIO N OF 
GERM LINE M UTATIONS IN THE BRCA1  GENE
The following st rategies used for detect ion o f  the mutations in 
the BRCA1 gene:
• Genomic  DNA was used for this study.
• The entire BRCA 1 gene was screened by SSCP analysis
• The exon 11, which contains almost  two-thirds  o f  the 
BRCA1 coding sequence,  was also amplified for PTT 
analysis .
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In the presence of any abnormal band, direct sequencing was 
carried out to characterise the nature o f that extra band.
Each amplified fragment in the expected size range was subject 
to SSCP analysis and any change found from it was sequenced 
to detect and locate the position and the nature o f that particular 
mutation.
For exon 11, PTT analysis was also employed to detect any 
mutations, which could create a truncated protein.
Automated sequencing was carried out using an ABI Prism 373 
automated sequencer on those samples where changes were 
found by SSCP.
A summary o f sequence changes and the methods by which they 
were detected and characterised are shown in table 3.1. Each 
mutation will be discussed in detail.
3.3. MUTATION DETECTION USING SSCP
As RNA samples were not available in this study, SSCP 
analysis was employed to screen all samples for the presence o f 
mutations using the primers listed in tables 2.2, 2.3, and 2.4. 
The fragments in exon 11 were named after the primers used to 
amplify them. The findings are as follows:
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3.3.1. Positive Result from F ragm ent Exon 11N
SSCP analysis o f  fragment exon 11N (table 2.3) in patient 24 
showed a different band pattern in comparison to all the others 
patients in this study excluding patients sample no 13, 15, 28 
(figure 3.6). In order to understand the basis o f  this change, the 
sample was analysed by automated sequencing.
Figure 3.6: SSCP analysis of Exon 11 (fragm ent 11N) in 
BRCA1  gene. Silver stained MDE gel o f  SSCP analysis o t  
BRCA1 exon 1 1, showing a different single strand band in lane 
two (marked by an red arrow). Lane one was sample  23 
showing two single stranded bands, which co-migrated with 2 
bands in L2. The results seen in LI were the same as these 
found for all patients.
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3.3.2. Positive Result from Exon 13
SSCP analysis o f  Exon 13 showed that six out o f  the forty-eight 
patient samples (Table 3.1) had a unique single strand band 
pattern (Figure 3.7). These samples were subsequently 
sequenced.
LI L2 L3
19 7 24
Figure 3.7: SSCP analysis of Exon 13 in BRCA1  gene.
Sample no: 19,24. Silver stained MDE gel o f  SSCP analysis o f  
BRCA1 exon 13, showing different  single strand band pattern in 
lanes one and three (marked by red arrows). Lane two was 
sample no 7, showing two single stranded bands, which were 
co-migrated. Samples 19 and 24 show the band pattern found in 
6 patients (figure 3.1). Sample  7 shows the band pattern found 
in the other 42 patients.
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3.3.3. Positive Result from  Exon F ragm ent 11C
The silver-stained MDE gel o f  SSCP analysis o f  BRCA1 gene 
fragment exon 11C. The sample from patient no 30 pattern 
showed a shifted band compared to other samples tested. The 
fragment exon 11C was subsequently sequenced from patient no
30.
LI L2 L3
Figure 3.8: SSCP analysis of Exon 11 (fragm ent 11C) in 
BRCA1  gene.. Silver stained MDE gel o f  SSCP analysis o f  
BRCA1 exon 1 1, showing a shifted band from sample no: 30 in 
lane one (marked by red arrows). There are two co-migrated 
band at the level o f  single strands in lanes two and three 
(sample no: 31,32).
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3.3.4. Positive Result from Exon F ragm ent U N
SSCP analysis from fragment exon 11N (table 2.3) a revealed 
different single strand band pattern in patient 13 compared to all 
other samples. This clearly indicated a possible mutation in this 
position. The fragment was subsequently sequenced using an 
ABI Prism 373 automated sequencer.
LI L2 L3
13 27 29
Figure 3.9: SSCP analysis of Exon 11 (fragm ent U N ) in 
BRCA1  gene. Silver stained MDE gel o f  SSCP analysis o f  
BRCA1 exon 1 IN, showing a different single strand band 
pattern from sample no: 13 in lane one (marked by red arrows). 
Lanes two and three show two co-migrated single strands 
(sample no: 27,29) typical o f  all other samples analysed.
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3.3.5. Positive Result from Exon 20
The PCR amplification o f  exon 20 in patient no 2 resulted in an 
extra band when analysed by agarose gel electrophoresis 
(Figure 3.11). The fragment was also analysed by SSCP and an 
altered band pattern detected compared to all other samples 
analysed (Figure 3.10).
LI L2 L3
Figure 3.10: SSCP analysis of Exon 20 in BRCA1  gene.
Sample no: 2. Silver stained MDE gel o f  SSCP analysis o f  
BRCA1 exon 20, showing heteroduplex bands in lane two 
(marked by red arrow). There is a clear difference in single 
strand band pattern in lane two (marked by green arrows). Lane 
one and three show no heteroduplexes and two co-migrated 
single stranded band (sample no: 19,21).
82
*232 bp 
220 bp 200 bp
1 2 3 4 5
Figure 3.11: The PCR am plification of exon 20 from  BRCA1
gene. The PCR amplified products o f  exon 20 were analysed in 
a 1% agarose gel. The target DNA length is 220 bp. Lanes one 
and five are 50 bp DNA markers.  Lane two shows an extra 
DNA band in patient  no 2 suggesting that there is an insertion 
in one allele on this sample.  Lanes three and four are patients 
no 3 and 4 and are typical o f  all samples analysed.
3.4. M UTATION DETECTION USING PTT
As RNA samples were  not available  in this study, PTT analysis 
could only be applied to exon 11, which was amplified with 
three overlapping sets o f  primers (Table 2.5). It was carried out 
by adding 8jul DNA in DEPC treated water  to the T N T K Lysate 
Coupled  Transcrip tion/Translat ion System (Prom ega  cat no. 
L4610) and fo llowing the manufacturer  inst ruct ion (Section
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II.7.2.2). A positive control translation reaction using 
Luciferase DNA (supplied by the manufacturer) and a negative 
control translation reaction were carried out by performing 
transcription/translation without adding DNA to analyse the 
efficiency of the system. The synthesised protein products were 
separated by 12.5% SDS-polyacrylamide gel electrophoresis. 
The gel was then autoradiographed for 48-96 hours. The three 
optimised PTT results are shown in figures 3.12-14.
However, the efficiency o f PTT analysis was not always 
satisfactory. In order to improve the efficiency o f PTT analysis, 
the following parameters were altered.
1. PCR amplified products were purified using a GFX™ 
DNA purification kit (Pharmacia Biotech) and the 
concentration was obtained by spectrophotometry. The 
intensity of the band produced from the product purified 
was also compared with the intensity o f the band from the 
control DNA supplied with the kit.
2. The translation reaction time was increased up to 100 
minutes.
3 53. In order to increase the sensitivity of detection o f S, the 
gel was treated with Amplify™ solution (Amersham) for 
20 minutes.
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Wild Type 
Protein46 KD
30 KD
21 KD
Figure 3.12: The PTT analysis  result from fragment I in 
exon 11. Using an 12.5% SDS polyacrylamide gel. A red arrow 
indicates the wild type protein produced from patient sample 
nos 10, 11, 12. Nonetheless, a truncated protein could not be 
found in this fragment. The first lane is a rainbow protein 
marker ranging from 21 to 46 KD.
46 KD
Wild Type
30 KDP ro te in
2 7 2 8 21 KD
Figure 3.13: The PTT analysis  result from fragment II in 
exon 11. 12.5% SDS polyacrylamide gel. A red arrow indicates 
the wild type protein produced from patient sample nos 27, 28. 
Nonetheless, a truncated protein could not be found in this 
fragment. Lane 4 is a rainbow protein marker. L3 is the weakly 
produced wild type protein.
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Wild Type 
Protein
LI 20 21
Figure 3.14: The PTT analysis  result from fragment III in 
exon 11. 12.5% SDS polyacrylamide gel. A red arrow indicates 
the wild type protein produced from patient sample nos 20, 21. 
Nonetheless, a truncated protein could not be found in this 
fragment. The first lane is rainbow protein marker.
3.5. CH ARACTERISATION OF THE MUTATIONS  
FOUND BY AUTO M ATED SEQUENCING
Automated sequencing o f  the PCR products was carried out 
using the “Thermo sequenase  II dye terminator cycle 
sequencing premix kit1' (Amersham cat no. US80975). The 
samples that were screened and gave positive results by SSCP 
analysis were subjected to sequencing o f  the PCR products  from 
the corresponding DNA segment(s)  which were reproduced for 
automated sequencing analysis. 4/// double-stranded DNA (40- 
400 fmol) template in ddH 20  was used according to the 
m anufacturer’s instruction. In order to purify the product, the
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GFX™ DNA purification kit and the purification solutions 
provided with the sequencing kit were employed as described in 
section 2.6.1 and 2.7.3.2. The sequencing was carried out with 
the air-dried pellet in 4jul o f gel loading mix provided with the 
kit.
The analysis o f the sequence was carried out using the 
Macintosh computer attached to the PRISM 373 DNA system, 
using the 373A software (ABI). The computer processed the 
data and presented it as a chromatogram with four coloured 
peaks (G=black, T=red, C=Blue and A=Green). Heterozygosity 
is represented by two superimposed peaks.
The positive results discussed under the section 3.3 will be 
discussed in further detail.
3.5.1. Polymorphism at Nucleotide Position g.3667 A>G
The automated sequencing from the positive sample mentioned 
in section 3.3.1 showed a base change from A to G at the 
nucleotide position 3667 (figure 3.15). This base change is 
predicted to produced the conversion o f the amino acid Lysine 
to Arginine (amino acid position: 1183). It was published and 
categorised as a polymorphism in the Breast cancer Information 
Core database (http://www.nhgri.nih.gov/). In this study, four 
out o f forty-eight patients (samples no, 13, 15, 24, 28) were 
found to have this polymorphism (table 3.1). These patients 
were registered in the database mentioned above and the 
registration information was detailed in table 3.2.
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3.5.2. Polymorphism at Nucleotide Position g.4427 T>C
The automated sequencing of the positive sample mentioned in 
section 3.3.2 showed a base change from T to C at the 
nucleotide position 4427 (figure 3.16). This was the most 
frequently published polymorphism according to the Breast 
cancer Information Core database (BIC)
(http://www.nhgri.nih.gov/). It results in a silent mutation at a 
serine amino acid, position 1436. In this study, six out of forty- 
eight patients (sample nos, 1 , 4 ,  19, 24, 36, 62) were found to 
have this mutation (table 3.1). These patients were registered in 
the database mentioned above and the registration information 
was detailed in table 3.2.
3.5.3. Point Mutation at Nucleotide Position g.3771 A>T
The automated sequencing of the positive sample mentioned in 
section 3.3.3 showed a base change from A to T at the 
nucleotide position 3771 (figure 3.17). This mutation found in 
BRCA1 fragment exon 11N was first published in the Breast 
cancer Information Core database (BIC)
(http://www.nhgri.nih.gov/) as a novel mutation. This mutation 
is predicted to cause an amino acid change from Serine to 
Cysteine (amino acid position: 1218). In this study, two out of 
forty-eight patients (sample nos, 13, 28) were found to have this 
mutation (table 3.1). These patients were registered to the 
database mentioned above and the registration information was 
detailed in table 3.2.
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3.5.4. Point Mutation at Nucleotide Position g.1380 G>A
The automated sequencing o f the positive sample mentioned in 
section 3.3.4 showed a base change from G to A at the 
nucleotide position 1380 (figure 3.18). This mutation found in 
BRCA1 fragment exon 11C was first published in the Breast 
cancer Information Core database (BIC) 
(http://www.nhgri.nih.gov/) as a novel mutation. This mutation 
is predicted to cause an amino acid change from Glutamine to 
Lysine (amino acid position: 421). In this study, two out of 
forty-eight patients (sample nos, 30, 36) were found to have this 
mutation (table 3.1). These patients were registered on the 
database mentioned above and the registration information was 
detailed in table 3.2.
3.5.5. U. Variant at Nucleotide Position g.5396+60 insl2bp
The automated sequencing o f the positive sample mentioned in 
section 3.3.5 showed an insertion of 12bp 
(insGTATTCCACTTC) at the nucleotide position 5396+60 
(figure 3.19). This mutation found in BRCA1 intron 20 has been 
published in the Breast cancer Information Core database. In 
this study, one out o f forty-eight patients was found who had 
this mutation (table 3.1). The nature and effect o f this mutation 
is still not clear. Further details of this mutation will be 
discussed in the next chapter. This mutation was registered to 
the database mentioned above and the registration information 
was detailed in table 3.2.
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3.6. POSSIBLE LARGE DELETION IN SAMPLE 28
The sequencing  o f  sam ple 28 for fragm ent exon 11N (figure
3.15) show ed a G at position 3667. The normal sequence has an 
A at this position. The result could be due to hom ozygosity  at 
this base or to the presence o f  one allele contain ing  the A>G 
change and the other allele deleted for this region. To identify 
w hether a small deletion within the exon 1 1 was present, the 
Expand Long Tem plate  PCR analysis was em ployed (section
2.7.3.). Primers published  by Payne et al. (2000) were used to 
am plify  the region contain ing  exon 1 1 , 1 2  and intron 11 (figure
3.1)The analysis o f  the fragm ents produced  by this 
am plification are shown in figure 3.20.
L 28 29 30 L2
9 kb 9.5 kb
kb
Figure 3.20: E xpand Long T em plate PCR Anddfsj lQQbp
product encom bassing  exon 11, 12 and intron 11 were analysed 
in a 0.7% agarose  gel. Lane one and five are DNA m arkers (1 
kb and 100 bp respectively). Sam ple 28, show ed the same band 
size as those am plified  from  patients 29 and 30.
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3.7. POLYMORPHISM FREQUENCIES IN A 
CONTROL GROUP FROM THE WEST OF 
SCOTLAND
Two widely published polymorphisms (g.4427 T>C, g.3667 
A>G) and one intronic insertion o f 12 bp (g.5396+60 insl2bp) 
were found in this study. The frequency of these mutations in a 
normal population from the West o f Scotland was unknown. In 
order to establish the frequency of these mutations in a normal 
population, 100 DNA samples were obtained from the medical 
genetics department at the Duncan Guitre Institute o f Medical 
genetics, Glasgow. These samples were anonymatised control 
samples from a consented normal West of Scotland population. 
SSCP analysis was employed to find out the frequency of two 
single base-pair polymorphisms and positive results were 
subsequently sequenced. The 12 bp insertion in intron 20 was 
analysed by PCR. Size differences between two alleles in each 
sample was investigated by analysing products in a 1% agarose 
gel.
3.7.1. Analysing Polymorphism g.5396+60 insl2bp in the 
Control Group
One hundred control samples were analysed by PCR using the 
primer set for exon 20 (section 2.4.1.). Samples were size separated 
by 1% agarose gel electrophoresis and visualised using ethidium 
bromide. None of the control samples were found to have this 
insertion in their intron 20 of BRCA1 gene (figure 3.21)
96
^ - ■ * 1  c  4 8 28 38 43
Figure3.21: The PCR am plification of exon 20 from  B R C A l  
gene. The PCR amplified products o f  exon 20 were analysed in 
a 1% agarose gel. Lane one is a DNA m arker (10 bp) and 100, 
200 bp are indicated by black arrows. Samples no 4, 8, 28, 38, 
43 showed no extra  band in comparison to the positive control 
(C) suggesting that there was not an insertion in intron 20.
3.7.2 Analysing Polym orphism  g.4427T>C in C ontrol G roup
One hundred control samples were analysed by SSCP analysis 
(section 2.7.1.) using an M D E gel and silver staining to 
visualise the samples (figure 3.22). Ten control samples out o f  
100 were found carrying polym orphism  g.4427 T>C. the 
presence o f  this polym orphism  was subsequently proved by 
autom ated sequencing (section 2 .7.4)(figure 3.23). Control no 
11 was found to only have C at bp 4427. This could indicate 
hom ozygosity for this polymorphism , (figure 3.24).
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3.7.3 A nalysing Polym orphism  g.3667A>G in C ontro l G roup
One hundred  control samples were analysed by SSCP analysis 
using prim er set 11N (table 2.3). Using M D E gel and silver 
staining, sam ples were visualised (figure 3.25). Six control 
samples out o f  100 were found carrying polym orphism  g.4427 
T>C and this w as subsequently confirm ed by autom ated 
sequencing (section 2 .7 .4)(figure  3.26).
Figure 3.25: SSCP analysis of the fragm ent Exon 11N. Silver 
stained MDE gel o f  SSCP analysis o f  BRCA1 gene, the fragment o f  
exon 1 IN. First lane is a positive control (C). Samples no 10, 22, 37, 
44 showed a clear difference in the single strand band pattern in 
comparison to the positive control (marked by green arrows). The 
single strands in sample no 45 (marked by red arrow) is co- 
migrating with the band in polymorphism samples and is related to 
the normal sequence for this fragment.
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PATIENT 
ID NO
SAMPLE
ID
DATABASE 
ENTRY NO
DESIGNATION
MUTATION
TYPE
14830 13 4147 g.3667 A>G Polymorphism
14107 28 4150 g.3667 A>G Polymorphism
13928 15 4148 g.3667 A>G Polymorphism
12945 24 4149 g.3667 A>G Polymorphism
10645 1 4174 g.4427 T>C Polymorphism
11246 4 4175 g.4427 T>C Polymorphism
11500 19 4177 g.4427 T>C Polymorphism
12945 24 4178 g.4427 T>C Polymorphism
11243 36 4176 g.4427 T>C Polymorphism
16529 48 4179 g.4427 T>C Polymorphism
13632 36 4082 g.1380 G>A
Missense
Mutation
14213 30 4081 g.1380 G>A
Missense
Mutation
14830 13 4152 g.3771 A>T
Missense
Mutation
14107 28 4153 g.3771 A>T
Missense
Mutation
12418 2 Pending
g.5396+60 ins 
12bp
Unclassified
Variant
Table 3.2: Mutations registered with the Breast Cancer 
Information Core Database.
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CHAPTER 4
DISCUSSION
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4.1 MUTATION SPECTRUM IN THE BRCA1 
GENE
M utations in the BRCA1 gene are thought to account for m ost 
o f  fam ilial ovarian  cancer. These m uta tions include nonsense  
m uta tions, small deletions and insertions causing  fram esh if t  
m uta tions, m issense  m uta tions occurring  at crucial am inoacid  
positions w ithin  w ell-conserved  dom ains and m uta tions 
affecting  the splice sites.
A ccord ing  to the B reast C ancer Inform ation  Core database  
(BIC), m ore than 850 d ifferen t m uta tions in the BRCA1 gene 
have been reported  out o f  nearly  4000 entries. In addition ,
Others
10%
Polymorp
Missense
Mutations
29%
Nonsense
Mutations
11%
Frameshift
Mutations
45%
Figure 4.1: D istribu tion  of BRCA1  m utations.
m s
more than 500 (57%) of them were reported only once. 
(http://www.nhgri.nih.gov/intram ural_research/Lab_transfer/). 
Almost 2250 (56%) o f the mutations are nonsense mutations 
and frameshift mutations including, small insertions, deletions, 
splice variants and regulatory mutations that result in 
truncation or absence o f the BRCA1 protein (figure 4.1).
More than 1150 (29%) of those entries are m issense mutations 
that are predicted to result in an amino acid changes in the 
coding sequence and more than 240 (5%) polymorphism s and 
nearly 500 (10%) o f those entries are silent m utations and 
unclassified variants have been reported to the database.
The most common mutations are 185 delAG and 5382 insC 
which account for 490 (12%) and 270 (7%) respectively, o f all 
mutations reported so far. The mutations are spread over the 
entire length o f the coding sequence (figure 4.2).
The frequency o f mutations varies greatly depending on the 
racial or ethnic group. In general, it is lower than expected 
from data based on families identified by linkage analysis 
(Szabo & King MC., 1997). In a recent report from the Breast 
Cancer Linkage Consortium, it was estimated that only 63% of 
all families linked to BRCA1 have a mutation detectable by 
standart screening methods (Ford et al., 1998), thus suggesting 
that other types o f gene activation might account for some of 
the predisposed kindreds. To date, an inhibition o f BRCA1 
transcription by regulatory mutations has been rarely reported
106
(Miki et al., 1994; Gayther et al., 1995; Xu et al., 1997a; 
Serova et al., 1996).
M ajor genomic rearrangem ents o f the BRCA1 gene including 
deletions, which escape most o f the current PCR-based 
mutation detection methods, are likely to account for at least 
some o f the cases without apparent BRCA1 mutations (Petrij- 
Bosch et al., 1997; Swensen et al., 1997; Puget et al., 1997). 
This possibility is also supported by the high density o f Alu 
repeats dispersed in the BRCA1 genomic sequence (Smith et 
al., 1996) and Alu  sequences can mediate major genomic 
rearrangem ents by promoting unequal crossing-over or other 
types o f recom bination.
In a study from Holland (Petrij-Bosch et a l ., 1997) reported 
that repetitive finding o f a 510 bp ^4/w-mediated deletion 
comprising exon 22 and a 3835 bp ^4/w-mediated deletion 
comprising exon 13 were responsible for 36% o f all BRCA1 
mutations found in Dutch breast cancer families to date. These 
had not been detected by PCR-based m utation screening 
methods.
BRCA1 m utations which are detectable using commonly 
employed PCR-based techniques are small insertions, deletions 
or single base-pair substitutions. These comprise m ost germ- 
line m utations in high risk families but rarely occur as somatic 
mutations (Hosking et al ., 1995; Berchuck et a l., 1998b; 
M atsushima et al., 1995; Takahashi et al., 1995). On the other 
hand, large deletions concerning sizes of mega-bases in the 
BRCA1 gene identified by loss o f heterozygosity (LOH), occur 
frequently in both inherited and sporadic breast and ovarian
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cancer (Devilee & Cornelisse, 1994). It was therefore 
suggested that large deletions in BRCA1 gene could also be 
responsible from some of the somatic breast and ovarian 
cancer cases.
In the absence of suitable assays to study the effects of 
aminoacid changes on BRCA1 protein function, the 
identification o f a missense m utation with functional 
consequences relies on indirect evidence. M issense mutations 
associated with a disease state suggest a functional 
significance of the aminoacids involved and in their location. 
Important amino acids would be expected to be conserved 
across species. Sequenced analysis o f BRCA1 reveals several 
possible protein motifs (figure 1.1). The RING finger m otif 
(aminoacids 24-64) is the most highly conserved. It is 100% 
preserved among known human RING finger domains and only 
a single aminoacid substitution (K55R) is found in canine and 
murine species (Szabo et al., 1996). It has also been reported 
that a repeatedly published missense m utation, Cys61Gly, 
which leads to an alteration of the sixth cysteine of the 
putative RING finger domain, could result in a deleterious 
effect by cousing the loss o f lost w ild-type allele in patients 
tumour tissue (M erajver et al., 1995). It has also been reported 
that a particular missense mutation (R841W) found in patients 
with a family history is related to the late age o f onset o f 
disease (Janezic et al., 1999).
Some other published missense mutations which result in 
changes in conserved protein domains are found in patients 
with a family history. However, until a functional assay is
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available, missense mutations and their role in tumorigenesis 
remain unknown.
Polymorphisms are defined as non-pathogenic variations in the 
normal gene sequence. It has been also reported that almost 
none o f the aminoacids that reported as polym orphic variation 
are conserved in murine and canine species (Sharan et al., 
1995). However, the effect o f polymorphisms on BRCA1 gene 
function is unknown. Narod et al. (1998) suggested that allelic 
variation o f host gene might influence the course o f cancer. He 
also suggested that genetic variations could influence the 
prognosis o f cancer, including grade, stage and other relevant 
prognostic factors. In addition, some polymorphisms in some 
genes may carry a functional importance and may create a 
mutation hot spot. For example, in Ashkenazi Jewish 
colorectal cancer patients, a polymorphism (I1307K) in the 
APC gene has been shown to create a m utation hot spot. 
Although, polymorphisms role in tum origenesis is not clear, 
polymorphic variants could be used as a m arker for analysing 
large deletions. Using patien t’s both DNA and cDNA for 
highly frequent polymorphic sites (providing that patient has a 
polymorphism ), heterozygous polymorphisms in genomic 
DNA located the distal or proximal part o f the BRCA1 gene 
from suspected large deletion might be found homozygous 
from the individual’s cDNA for the same loci (Swensen et al., 
1997; Catteau et al., 1999). This
109
4.2 MUTATION ANALYSIS
In this study, 48 ovarian cancer patients with a family history 
o f breast and/or ovarian cancer have been screened for 
germline mutations in the BRCA1 gene. The patients had 1-6 
affected family members with onset o f disease between 22-78 
years o f age (table 2.1). The mean age o f onset o f ovarian 
cancer with BRCA1 alterations was 50 years.
PTT and SSCP analysis was employed to detect changes as 
described in section 2.7.1-2. The characterisation of those 
changes was achieved by automated sequencing analysis as 
described in section 2.7.3.
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4.3 MUTATIONS IN THE BRCA1 GENE
A total o f 5 different alterations were detected in 15 of the 48 
ovarian cancer patients analysed (table 3.1). Two of those 
alterations, g.1380 G>A and g.3771 A>T were novel.
4.3.1 BRCA1  Gene Polymorphisms
Two polymorphisms were detected in the patient group. The first, 
g.3667 A>G, was found in four out of forty-eight patients and the 
second, g.4427 T>C, was found in six out of forty-eight patients 
(table 4.1).
These two polymorphisms are the most frequently found in ovarian 
cancer cases and the normal population. In our study, frequency of 
g.3667 A>G polymorphism in a control population was 6 in 100 and 
the g.4427 T>C polymorphism in a control population was 10 in 
100 .
The frequencies found in the study published by Durocher et al. for 
polymorphisms g.3667 A>G were 30% for patient population and 
32% for normal population and for polymorphisms g.4427 T>G, 
they were 30% for patient population and 33% for normal 
population. One other study published by Janezic et a l  has revealed 
the frequencies for polymorphism g.3667 A>G were 49% for patient 
population and 38% for normal population and for polymorphisms 
g.4427 T>G, they were 50% for patient population and 41% for 
normal population (table 4.1). The difference between published 
frequencies and the frequencies found in this study is noticable. The 
control and patient population published by Durocher et a l  were 
French-Canadians from Quebec, the control and patient population 
published by Janezic et a l  were from California, USA. Although,
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there is a noticable frequency difference between first two study and 
the present study, Scottish population is a well-conserved population 
and frequency for some other genetic mutations can vary even 
between England and Scotland (for example, Cystic fibrosis 
mutation R117H is four times higher in Scotland than it is in 
England, Kazazian et al., 1994). Furthermore, polymorphism g.3667 
A>G was also reported 1 out of 7 non-breast cancer patients (15%) 
(Shen et al. 2000) with Hispanic origin and 1 in 15 breast-ovarian 
cancer patients (7%) from Sweden (Johannsson et al. -1996). In 
addition, one study has reported that there was 3 times difference for 
polymorphism Gln356Arg between Breast cancer patients and 
ovarian cancer patients (Duning et al. 1997). Studies published by 
Durocher et al. and Janezic et al. mentioned above was patients who 
had a breast cancer. Therefore, the significant frequency difference 
might have happened because of population and cancer type 
difference.
In addition, the 12 bp insertion in intron 20 found in one patient in 
this study and none of the control samples tested had the same 
alteration. On the other hand, a study from Poland has reported that 
5 out of 122 patients with breast and ovarian cancer and 2 out of 236 
control samples had the same chance in their BRCA1 gene (Sobczak 
et al., 1997). This may further support that polymorphism 
frequencies may vary in different ethnicities.
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Although the polymorphisms are generally thought to be a 
benign variation in the gene sequence, histopathological 
studies suggest that the aggressiveness o f tum our progress, the 
histological type and the survival rate may be related to the 
presence o f these polymorphisms (Narod, 1998).
One study on prostate cancer reported that a polymorphism in 
the androgen-receptor gene is associated with a doubling o f the 
risk o f the cancer spreading beyond the prostate (Giovanucci et 
al., 1997). However, the polymorphisms and their role in 
cancer development are still unclear.
BRCA1
Poylmorp.
Predicted 
effect on 
coding  
sequence
Allele  
frequencies 
(a) A (b)
Allele  
frequencies 
(a) B (b)
Allele  
frequencies 
(a) C (b)
g.3667A>G Lys > Arg 57/182, 50/156  30% 32%
49/100, 38/100  
49% 38%
4/48, 6/100  
9% 6%
g.4427T>C Ser > Ser 72/238, 55/166  30% 33%
50/100, 41/100  
50% 41%
6/48, 10/100  
13% 10%
Simplified figures (%)
Table 4.1: The polymorphisms and their frequencies in
ovarian cancer patients (a) and normal population (b). The 
frequencies in column (A) were published by Durocher et al. 
(1996), column (B) was published by Janezic et al. (1999), and 
column (C) was found in this study.
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4.3.2 Two Novel M issense M utation in BRCA1 Gene
Two novel missense mutations were detected in the BRCA1 
coding sequence. The mutations, g.3771 A>T, and g.1380 
G>A, were found in two out o f the forty-eight patients tested. 
The mutation, g.3771 A>T, is predicted to result in an amino 
acid change from serine to cysteine at position 1218. This 
would alter the granin site (amino acids 1214-1223) and the 
leucine zipper (amino acids 1209-1230). An indication o f the 
functional importance of a sequence motif, is the conservation 
of that particular m otif across species. The granin consensus 
sequence is completely conserved in other secreted human 
proteins including BRCA1, and except for one amino acid 
(1216), the murine and the canine species are also conserved in 
the granin m otif (Szabo et a l ,  1996). Biochem ical 
characterization suggests that human BRCA1 shares functional 
features as well as sequence sim ilarity with the granin family 
of proteins (Jensen et al., 1996). The same author suggested 
that BRCA1 is a secreted protein and that its secretion is 
triggered by activation of cyclic AMP, and induced by 
estradiol. Further studies have also identified that BRCA1 is 
also present in the golgi complex. Jensen et al. also reported 
the following points.
• The granins are acidic with isoelectric points between 
4.9 and 5.6; the predicted isoelectric point o f BRCA1 is 
5.2.
• They both have 15-25% acidic residues.
• Both are localised in secretory vesicles.
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• The granin was shown to be regulated by estrogens 
(Fischer-Colbrie, 1991) as was BRCA1 (M arquis et al., 
1995).
• BRCA1 and granins are both heat stable.
Like other well-conserved domains in the BRCA1 gene, granin 
could be a very important component for the normal 
functioning o f the BRCA1 protein.
The serine to cysteine mutation reported here would be 
expected to be pathological. It is well established that cysteine 
has a very important role in stabilising three-dim ensional 
protein structure. Two cysteine residues in different parts of a 
polypeptide chain but adjacent in the three-dim ensional 
structure o f a protein can be oxidised to form a disulfide 
bridge. Disulfide bridges usually occur in secreted proteins and 
make the protein less susceptible to degradation (Branden & 
Tooze, 1991).
The presence o f this new cysteine in the BRCA1 protein could 
destabilise the protein’s three-dim ensional structure by 
forming an inappropriate disulfide bridge. It is possible that 
this change may also lead to molecular degregation and a 
lower level o f BRCA1 expression.
The second missense mutation, g.1380 G>A, is predicted to 
cause an amino acid change from glutamic acid to lysine at 
amino acid position 421. The effect o f this m utation on the 
BRCA1 protein is unknown. However, this amino acid is 
conserved in the murine BRCA1 sequence (Sharan et al., 1995;
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Jensen et al., 1996). Almost all of the missense mutations that 
are associated with the disease in humans were in amino acids 
that are conserved between human and murine species. In 
contrast, most o f the amino acids that are involved in 
polymorphic variations are not conserved between species. 
This suggests that the interspecies conservation o f predicted 
amino acid sequences could be a functional conservation. 
These two studies suggest that a certain proportion of 
uncharacterised variants (missense m utations) may affect 
BRCA1 function and increase the breast and ovarian cancer 
risk.
The predicted amino acid change is from glutamic acid to 
lysine and both amino acids are in the “charged amino acids” 
group. However, glutamic acid is negatively charged whereas 
lysine is positively charged. The glutamic ac id ’s isoelectric pH 
is 3.24 and, lysine’s isoelectric pH is 9.12. This amino acid 
change from acidic amino acid to basic amino acid might 
therefore affect the net isoelectric charge o f the molecule (Ege, 
1994).
4.3.3 Unclassified Variant at Nucleotide Position g.5396+60
The insertion o f 12 bp (5 ’-GTATTCCACTCC-3’) in intron 20 
begins 60 bp downstream o f the 3 ’ boundary o f exon 20. This 
variant has been previously described in four cases by 
Takahashi et al. (1995) in five cases by Sobczak et al. (1997) 
and in one case by Robledo et al. (1997). In these three 
studies, the variant was not present in any o f the subjects in 
the control population analysed. It was also reported that this
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variant did not modify the correct splicing o f exons 19-21 
(checked by analysing the cDNA obtained from the patien t’s 
peripheral blood).
However, Sobczak et al. (1997) reported that splicing errors 
might be present in other tissues e.g. ovary and breast. It was 
also suggested that a relatively large insertion in a region of 
non-repetitive DNA could affect the kinetics o f splicing and 
result in a lower level o f mRNA from the m utant allele. 
Furthermore, Robledo et al. (1997) reported that one case with 
the 12 bp insertion in intron 20 was also heterozygous for a 
common polymorphic site in exon 13 (g.4427 C>T). In that 
study, heterozygosity was also tested using cDNA covering the 
position of the polym orphism  mentioned. Loss of 
heterozygosity was found suggesting that the intron 20 
insertion created an unstable transcript.
Although, all reports suggest that the 12 bp insertion in intron 
20 could lead to an unbalanced BRCA1 protein function, 
drawing a firm conclusion requires further study.
4.3.4 Possible Large Deletion in BRCA1 Gene
The sequencing of sample 28 for fragment exon 11N (figure
3.15) showed a G at position 3667. The normal sequence has an 
A at this position. This result could be due to homozygosity at 
this base or to the possibility o f a large deletion, which included 
one or both o f the primer sites. For this polymorphism, 100 
control samples were selected to find out the frequency in the 
general population. Applying SSCP analysis and automated 
sequencing, 6 out of 100 control samples showed this
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polymorphism in their BRCA1 gene (discussed under section
4.3.1).
The Expand Long Template PCR Analysis was employed to 
identify any possible deletion that creates shorter amplified 
product (figure 3.20). Using a published primer set (section
2.7.3) by Payne et al. (2000), 9518 bp of genomic DNA was 
amplified, including exon 11, 12 and intron 11 (figure 4.3). The 
result showed that there was no deletion within the amplified 
region. Southern blotting would be the next choice o f analysis 
to detect any large deletion in this area using the 9518 bp 
product as a probe.
However, there was no positive control within the region for 
analysis to compare our possible deletion sample. Southern 
Blotting technique will be informative when a positive control 
within the probe region and sample can be tested together for 
dosage effect.
Not knowing the size of the putative large deletion covering 
exon 11, increasing the size o f probe until the probe includes a 
known deletion was not feasible. Therefore, The Fluorescence 
In Situ Hybridisation (FISH) which can detect a large deletions 
from 40 kb from a genomic DNA sample (Trask, 1991; Grange 
et al., 1987) might be the next choice to detect any large 
deletion in the interested area.
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Figure 4.3: Detection strategies for possible deletion in Exon 11 
in BRCA1 gene: Possible large deletion that includes Exon 11 has 
been searched for due to the presence o f  possible homozygous 
polymorphisms, g.3667 A>G (indicated by red star).
1. In order to prove that there was no deletion at primer sites for 
fragment exon I IN, 220 bp, (indicated by blue double arrow) 
amplified product containing elements from both alleles (if 
there was no deletion), two other sections o f  Exon 11 
(fragment Exon 11M, 270 bp and 110, 289 bp)(table 2.3), 
covering primer sites for fragment U N  was also amplified 
and SSCP analysis was performed (indicated by two red 
double arrows).
2. Applying Expand Long Template PCR analysis (section
2.7.3), Exon 11, 12 and Intron 11 have been amplified (the 
area amplified indicated by green double arrow) and a 
minimum 100 bp product could be visualised (figure 3.20). A 
large deletion within described area has not been found.
3. The possibility o f  a deletion larger than amplified part o f  
BRCA1 gene could be detected by FISH analysis and 
providing a positive control by Southern analysis.
1 9 0
There is only one large deletion published that included exon
11. This was a 23.8 kb deletion that encompassed exon 8 to 13 
(Puget et al., 1999) (table 4.2). Presumably, the large size of 
exon 11 might not easily allow the Alu elements in the BRCA1 
intronic regions, which may promote unequal crossing-over, to 
create intragenic recombination and deletion.
In addition to the argument, the possibility o f homozygosity in 
our sample for polymorphism g.3667 A>G is much higher than 
the same sample having large deletion that includes exon 11. 
From control samples, the frequency of this polymorphism was 
found in 6 out o f 100 samples and the ratio that both parents 
have the same polymorphism is the same as control population. 
This gives us a 1 in 1102 chance of passing both polymorphic 
alleles to the next generation (6/100x6/100x1/4). On the other 
hand, one study from Holland (Petrij-Bosch et a l ., 1997) has 
shown no large deletion comprising exon 11 in 170 breast and 
ovarian cancer patients and considering this published data, the 
possibility o f having one parent a polymorphism and the other 
parent a large deletion, which includes exon 11, would be much 
lower.
Without excluding the possibility o f a large deletion in BRCA1 
gene in sample 28, evidence suggests that a homozygous 
polymorphism is much more likely.
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4.4 DIFFICULTIES AND LIMITATIONS WITH 
MUTATION SCREENING OF THE BRCA1 GENE
M utation screening was found to have difficulties and 
lim itations in this study.
This study was designed to screen for m utations in ovarian 
cancer patients retrospectively. Therefore, there was no 
opportunity to collect more blood from these patients for RNA 
experiments. Only DNA was prepared from the original blood 
samples.
Two missense mutations found in this study could not be 
tested for loss o f heterozygosity because o f the absence o f 
tumour tissues from these patients.
The BRCA1 gene is a com paratively large gene, spanning 
lOOkb on chromosome 17q21 and contains 24 exons. Screening 
a gene this size was very time consuming. Forty-seven sets o f 
primers were employed to detect mutations in the BRCA1 gene 
using SSCP analysis on 48 patient samples.
Even though the latest and the most advanced analysis kit 
(TNT® Lysate Coupled Transcription/Translation System) was 
used to detect any truncated proteins, the success rate o f 
producing a protein was approximately 50%.
The optim isation o f PCR conditions was more com plicated 
than for SSCP analysis because of the size differences between 
forward and reverse primers.
Because o f the absence o f RNA samples in this study, the 
m utation found in intron 20 could not be checked to see if  it 
had an impact on splicing between exon 20-21. The most
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important lim itation was whether or not all BRCA1 mutations 
were detected in this study. It has been reported that the 
success rate for SSCP analysis is nearly 100% if  the target 
DNA size is under 200bp. Almost all the targets in this study 
were above 300bp.
All samples used in this study had not been screened before 
and therefore detecting the success rate o f SSCP analysis for 
mutations was not possible. In addition, It has been reported 
(Ford et al., 1998) that mutation screening techniques might 
not detect mutations affecting expression or stability o f the 
protein and deletions o f large regions o f the gene.
On the other hand, the clinical interpretation o f the mutations 
found would be a challenge. The effect o f m issense mutations 
and polymorphism s on the BRCA1 gene is still uncertain 
because o f the absence o f a functional assay. Genetic testing 
based on family history and the age of onset for ovarian cancer 
may not be as valuable as they are for breast cancer. Therefore, 
results including m issense mutations and polymorphism s found 
in a patient with a family history and without ovarian cancer 
could be very difficult to interpret. Although hereditary breast 
ovarian cancer clinics have been established, the raw genetic 
data received, concerning missense m utations and 
polymorphism s, would be further a difficulty for the clinician 
who might already have problem s with m edical management o f 
patients who do not have the ovarian cancer.
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In addition, the ethical approach to the information obtained from 
genetic testing is very important. The conflict between respect for 
autonomy (the right not to know) and the responsibility towards 
future generations (the duty to know for the sake of one’s 
descendants) ought to be considered. Cancer susceptibility testing 
should remain confidential because, for example, the possible 
difficulty in securing employment and life, health or disability 
insurance. Therefore, genetic testing should also be evaluated for its 
general and specific ethical implications.
4.5 CONCLUSION
Ovarian cancer is the fifth most common female malignancy 
and the fourth-leading cause o f cancer death in the modern 
world. An understanding o f the molecular pathologies has 
advanced during the last decade. Screening for the mutations 
in a candidate gene is still the main strategy to characterize the 
hereditary alterations. It has been reported that 3-13% of all 
ovarian cancers are hereditary and the BRCA1 gene is 
responsible for 90% of familial ovarian cancers. However, the 
role of the BRCA1 gene in tumorigenesis is still not clear. The 
roles in transcriptional regulation and DNA repair have been 
proposed so far. In addition to functional uncertainty, 
localization of BRCA1 protein is also not clear. Because of the 
absence of a functional assay for BRCA1, the effect o f the 
missense mutations, unclassified variants and polymorphisms 
found in the BRCA1 gene remains to be unexplained.
The strategy o f using genomic DNA as a template for PCR 
am plification and the use o f SSCP and PTT as the main
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screening techniques has proved to be a useful screening 
strategy for the detection of mutations within the BRCA1 gene. 
However, recent studies reported that, large deletions and 
mutations affecting regulatory sites cannot be detected by 
these conversional PCR-based screening methods. Therefore, 
techniques that can detect those mutations such as Expand 
Long Template PCR analysis, Southern Blotting and even 
FISH should also be considered.
In this study, using the screening techniques, 5 different 
alterations were found. Although more than 50% o f the 
mutations reported in the BIC database are frameshift 
mutations, nonsense mutations, splice variants and regulatory 
mutations that create premature stop codons leading to 
truncated proteins, none o f them was found in this study. 
Because o f the absence o f any functional assay for BRCA1 
protein, most o f the published data focused on those types o f 
mutations that create truncated protein. On the other hand, 
nearly one-third of all mutations reported to the BIC database 
were missense mutations and their importance in BRCA1 
function could only be estimated by their localisation and their 
conservation in species. In addition, polymorphism s to date are 
accepted as variations in the gene with no effect on the 
function of the protein.
The mutation frequency in this study is lower than the 
published data. The reasons for this low mutation frequency 
may be that:
Some mutated cases may have escaped detection, because o f  
the technical insufficiencies o f the methods used.
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Mutant BRCA1 alleles bearing duplications, translocations or 
large deletions, which affect the target sequence for the PCR 
primers, are likely to remain undetected.
Testing possible sporadic cases because o f their small family 
size or large numbers of male descendants may give rise to 
false negative results. Only single individuals from each 
family were analysed, and it is possible that some of these may 
have been phenocopies.
Finally, BRCA1 is not the only gene responsible for 
tumorigenesis in ovarian cancer. BRCA2 is also responsible 
for more than 10% of all hereditary cases. As mentioned 
before, large deletion may not be detected; therefore, some of 
the unexplained familial cases can also be attributed by the 
presence of large deletions.
For the reasons mentioned above, it is probably prem ature to 
exclude the BRCA1 gene as a cause in all patients in whom we 
were not able to find mutations.
The control samples for frequency analysis o f polymorphisms 
g.3667 A>T and g.4427 C>T also showed lower frequencies 
for polymorphisms mentioned.
The carrier frequency for BRCA1 gene m utations is estimated 
to be 1 in 500 in the general population. Using the number of 
family members affected and the age of onset are the only two 
main diagnostic parameters used to make an intelligent 
selection for hereditary cases. M utation screening and 
characterisation in the BRCA1 gene has been and is difficult 
because o f its size. M utation detection technology has 
lim itations and is another factor adding difficulty to the
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screening strategies. Furthermore, the m utations are well 
spread over the entire length o f the coding sequence.
4.10 FUTURE WORK
Although, the BRCA1 gene has been cloned and a number of 
frequently encountered inherited mutations are recognized, the 
function o f BRCA1 protein in tumorigenesis is still not clear. 
Its relation to p53 and Rad51 and its function in transcription 
regulation and DNA repair mechanisms are so far only 
hypothesized. In addition, nearly half o f the m utations are 
m issense m utations, polymorphisms and unclassified variants. 
Because o f the absence o f any functional assay, their 
functional damage in BRCA1 cannot be established. Therefore, 
the development o f a functional assay will help, greatly, the 
identification o f mutations, which may lead to cancer.
As m entioned before, m utation screening in a gene of this size 
has many lim itations. Time and cost effectiveness will depend 
on the technique used and the selection o f patients for testing. 
The patients with a family history of breast and ovarian cancer 
and early age o f onset help to establish their hereditary status. 
Very recently, a m utation-screening project, for breast and 
ovarian cancer and involving this department, has been funded 
by the National Services Departm ent Scotland (NSD). The new 
technology known as “WAVE® HS Nucleic Acid Fragment 
Analysis System ” has been introduced. The accuracy in this 
system is provided by Temperature M odulated Heteroduplex 
Analysis (THMA) with fluorescently labeled DNA fragments.
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It is believed that this new system will provide much more 
accurate, sensitive, and rapid results.
Finally, as much as the determination to find m utations in the 
BRCA1 gene responsible for ovarian cancer is appreciated, the 
clinical importance o f the molecular findings must be 
determined. Proper guidelines and procedures for following a 
patient with a BRCA1 m utation with or w ithout ovarian cancer 
should be established.
In addition, an integral part o f a m utation screening program 
should be the counselling o f patients about the risks, benefits, 
likely outcomes and options o f testing and treatm ent. Patients 
who participate in a m olecular screening program  for ovarian 
cancer require substantial pre and post screening counselling.
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